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A key problem with animal models of psychosis lies with the animal’s inability to self-report its own 
internal state. In the present study, we used the drug discrimination paradigm, an assay that can 
provide an objective measure of an animal’s subjective internal state, to assess whether the subjective 
internal state experienced by rats that model a specific etiological schizophrenia risk factor (maternal 
immune activation; MIA) is analogous to that experienced in a model of human psychosis. After 
initial PPI testing, MIA (rats born from dams exposed to Poly I.C., a viral mimetic that produces 
activation of the immune system) and control rats, were trained to discriminate 7.5 mg/kg ketamine 
from saline in a two-lever operant chamber. Once discriminative control was established, dose-effect 
determinations were made. Controls procedures were conducted to rule out potential confounds 
resulting from MIA treatment, including, a pre-feeding challenge evaluating satiety as a non-drug 
internal cue and morphine discrimination to evaluate the rat’s performance with a drug cue unrelated 
to psychosis. Finally, an open field assay was conducted to investigate alterations in the sensitivity to 
ketamine-evoked hyperlocomotion. The results showed a deficit in PPI and impaired drug 
discrimination of ketamine in MIA rats, with the difference in discrimination between MIA and 
control particular to the psychotomimetic dose range (3-10 mg/kg). These results were not due to a 
deficit in the rat’s ability to learn or perform in the drug discrimination task, as MIA animals readily 
acquired morphine discrimination, a decreased sensitivity to ketamine, as MIA rats were actually 
more sensitive at psychotomimetic doses to ketamine-evoked hyperlocomotion, or a general decrease 
in sensitivity to internal states, as these animals were as sensitive to the satiety cue as their control 
counterparts. Overall these data provide support for the assertion that the subjective state of MIA rats 
is similar to that experienced in a ketamine model of psychosis and therefore may be analogous to that 
experienced in human psychosis. This indicates that the drug-discrimination paradigm may be a 
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1.1.1 Psychosis and schizophrenia  
Schizophrenia (SZ) is a chronic and severe mental disorder, characterised by a breakdown in the 
relationship between thought, emotion and behaviour, and a decreased ability to understand reality 
(Frith, 2014; Insel, 2010; World Health Organization, 2016). Modern neuroscience seeks to recognise 
SZ as a treatable brain disorder with a focus on identifying precise biological markers, yet so far, the 
neurobiological underpinnings of the disorder have remained elusive (Consortium, 2014; Sawa & 
Snyder, 2002; Tandon, Keshavan, & Nasrallah, 2008; Turetsky et al., 2006). While difficult to 
precisely quantify, the lifetime prevalence of SZ and related psychotic disorders is approximately 1% 
(Perälä et al., 2007). Active psychosis is ranked as the third most disabling condition worldwide 
(Ustun, Rehm, Chatterji, & Saxena, 1999), with a staggeringly high unemployment rate of 80-90% 
(Kooyman, Dean, Harvey, & Walsh, 2007; Marwaha & Johnson, 2004) and tragically ~4.9% of 
people with the disorder commit suicide (Palmer, Pankratz, & Bostwick, 2005). Patients with SZ have 
a reduced average life expectancy of 12-15 years and even with improving treatments this mortality 
gap is still widening (Saha, Chant, & McGrath, 2007). SZ is a disability incurring an estimated annual 
financial burden of 1.3 billion dollars in New Zealand alone, along with countless other intangible 
costs to patients, caregivers, family and society (Galletly et al., 2016). This substantial burden of 
disease is a reflection of two features of psychosis: 1) the onset usually occurs in adolescence to early 
adulthood  and extends throughout the lifespan (DeLisi, 1992), and 2) despite diagnosis and treatment  
approximately two-thirds of affected individuals experience severe persistent symptoms or chronic 





1.1.2 Schizophrenia: signs and symptoms  
The brain and behavioural dysfunctions of SZ fall into three broad symptom domains: positive, 
negative and cognitive. Positive symptoms are psychotic behaviours that are not normally seen in 
healthy people, e.g., delusions (fixed and false beliefs that do not respond to evidence) and 
hallucinations (false sensory experiences) (Andreasen & Olsen, 1982; Kapur, 2003). Negative 
symptoms are disruptions or a loss in normal emotions and behaviours, i.e., diminished affect and 
avolition (Andreasen, 1982; Kay, Flszbein, & Opfer, 1987). Finally, cognitive symptoms are 
expressed as a broad set of dysfunctions over the neurocognitive range including attention, executive 
functioning (the ability to understand information and make decisions) and memory (Addington, 
Addington, & Maticka-Tyndale, 1991; Kahn & Keefe, 2013). The clinical presentation of SZ is 
heterogeneous and no single symptom is definitive for diagnosis; rather, the diagnosis encompasses a 
pattern of signs and symptoms, in conjunction with impaired occupational or social functioning 
(Tandon, Nasrallah, & Keshavan, 2009).  
 
1.1.3 Aetiology of schizophrenia: genes to environment 
The aetiology of SZ includes genetic, neurochemical and environmental factors. Genetic factors have 
a substantial, but not exclusive, contribution to the aetiology of SZ; heritability estimates are ~80% 
for monozygotic twin studies (Cardno & Gottesman, 2000; Sullivan, Kendler, & Neale, 2003) and 64-
67% for family data (Lichtenstein et al., 2009; Wray & Gottesman, 2012). The variability in these 
estimates is due to the inherent difficulty of discretely partitioning genetic and environmental 
influences. Studies have identified different types of genetic variation including 11 rare copy number 
variants (CNV), >100 common variants and de novo variation as genetic risk factors (Consortium, 
2014; Fromer et al., 2016; Purcell et al., 2014). This suggests a polygenic model where a myriad of 
genes combine, each of which confers a small risk to the development of SZ (Broome et al., 2005; 
Kendler, 2015). Current variants from all genome-wide association studies (GWAS), however, can 
only account for 25-33% of total SZ liability, leaving a substantial amount of genomic heritability 
unaccounted for (Sullivan, Daly, & O'donovan, 2012). Some of the most significant genetic variants 
have recently been found to contribute to SZ risk during inflammatory complications in pregnancy 
(Ursini et al., 2018). Moreover, enrichment in the expression of SZ risk genes is higher in the placenta 
from male offspring compared to female (Bronson & Bale, 2016; Ursini et al., 2018), suggesting that 
gene-environment interactions influence placental biology and may contribute to the higher incidence 
of SZ in males (Bronson & Bale, 2014; J. McGrath, Saha, Chant, & Welham, 2008). 
 SZ genetic risk overlaps nosological categories, including mood disorders, (e.g., bipolar 
disorder (BD)), and neurodevelopmental disorders ranging from autism spectrum disorder (ASD) to 
intellectual disability (Moreno-De-Luca et al., 2013; M. J. Owen, O’Donovan, Thapar, & Craddock, 
2011; Rutter, Kim‐Cohen, & Maughan, 2006). With no clear boundaries existing between disorders in 
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clinical studies, there are likely to be overlapping mechanisms and this suggests that current 
diagnostic categories may not be optimal for stratifying cases into aetiology and pathogenesis (M. 
Owen, Sawa, & Mortensen, 2016). An integrated conceptualization of SZ as a disorder of 
neurodevelopment  (Murray & Lewis, 1987; Weinberger, 1987) proposes that environmental ‘hits’ 
interact with genetic vulnerabilities by perturbing development of the nervous system at critical 
periods, producing abnormalities that precipitate the later onset of the behavioural syndrome (Gogtay, 
Vyas, Testa, Wood, & Pantelis, 2011; J. J. McGrath, Féron, Burne, Mackay-Sim, & Eyles, 2003). 
Evidence has recently accumulated for epigenetic mediated interactions between obstetric 
complications and (Fatemi & Folsom, 2009; Tandon et al., 2009) premorbid impairments in childhood 
and adolescence (Jaffe et al., 2016; Maric & Svrakic, 2012; T. L. Roth, Lubin, Sodhi, & Kleinman, 
2009), linking genetic and environmental risk factors to an increased risk of SZ . The 
neurodevelopmental hypothesis can account for the heterogeneity found in the structural and 
anatomical abnormalities in SZ and may further help delineate meaningful diagnostic distinctions, 
which can act as guides to disease mechanisms and/or predictors of treatment response (Insel, 2014; 
Millan et al., 2016; Pantelis et al., 2005).  
 
1.1.5 Early life environment: prenatal infection 
Maternal Immune Activation (MIA) during the first and early second trimester has emerged as a 
significant etiological risk factor in the development of SZ (A. S. Brown & Derkits, 2009; Khandaker, 
Zimbron, Lewis, & Jones, 2013; Patterson, 2009). A long-standing association between prenatal 
infection and neurological disorders with neurodevelopmental features has been indicated by 
epidemiology studies, including: ASD, BD and SZ (A. S. Brown & Derkits, 2010; Jiang et al., 2016; 
Mednick, Machon, Huttunen, & Bonett, 1988); however, negative reports do exist (Bagalkote, Pang, 
& Jones, 2000; Selten, Frissen, Lensvelt-Mulders, & Morgan, 2009; Selten & Termorshuizen, 2016). 
A recent systematic review of serological assays or clinical assessment, has linked a range of 
pathogens (i.e., influenza, herpes simplex virus type 2, toxoplasma gondii, and bacterial infections) to 
an increased risk of developing psychosis by at least 2- to 3-fold in offspring (A. S. Brown, 2006; A. 
S. Brown & Derkits, 2010; Khandaker et al., 2013). Due to the low levels of pathogens detected in the 
placenta or the foetal brain, the effect on the offspring is hypothesised to be caused by the activation 
of the maternal immune system and an imbalance of pro- and anti-inflammatory cytokines, rather than 
resulting from a specific pathogen (Estes & McAllister, 2016; Garay, Hsiao, Patterson, & McAllister, 
2013; U. Meyer, Feldon, & Yee, 2009). However, while these associations provide a rationale to 
suggest that prenatal infection contributes to the origin of these disorders, they do not prove causality 
(Patrich, Piontkewitz, Peretz, Weiner, & Attali, 2016). 
 In line with this notion, mechanistic links are currently being investigated intensely in animal 
models (Estes & McAllister, 2016; U. Meyer, 2014; Reisinger et al., 2015). Multiple studies have 
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shown that after mimicking a viral infection, mainly during gestation day (GD) 14-16 in rodents 
(equivalent to the second trimester of human pregnancy) the progeny displays a broad range of SZ-
related anatomical, neurochemical, and behavioural deficits (Boksa, 2010; Luchicchi et al., 2016; U. 
Meyer, Feldon, Schedlowski, & Yee, 2005; Patterson, 2009). One of the most well-studied animal 
models of neurodevelopment psychosis is derived by exposing pregnant dams to the viral mimic 
polyriboinosinic-polyribocytidylic acid (poly I.C.), a synthetic double-stranded RNA viral mimetic. 
Following administration, poly I.C. binds to the Toll-like receptor 3 and initiates an acute maternal 
immune response that raises proinflammatory cytokines, including, interleukin-6 (IL-6), interleukin-8 
(IL-8), interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) in the placenta, amniotic 
fluid, and foetal brain (Ashdown et al., 2006; U. Meyer, 2011; Müller, Riedel, Gruber, Ackenheil, & 
Schwarz, 2000; Tomasik, Rahmoune, Guest, & Bahn, 2016). Poly I.C. induced MIA is sufficient to 
impart in the offspring a lifelong neuropathology, with behavioural impairments that appear in early 
adulthood and are commonly described in SZ patients, including, deficits in sensorimotor gating, 
temporal perception, latent inhibition, and social interaction (A. S. Brown & Derkits, 2010; Deane, 
Millar, Bilkey, & Ward, 2017; Osborne, Solowij, Babic, Huang, & Weston-Green, 2017; Zuckerman, 
Rehavi, Nachman, & Weiner, 2003). 
 
 
Figure 1.1 MIA is a primer for Schizophrenia. Reprinted from “Maternal immune activation: 
Implications for neuropsychiatric disorders,” by E. L. Myka and A. K. McAllister, 2016, Science, 
Volume (6301), page number 772. Copyright [2016] by American Association for the Advancement of 
Science (AAAS). Reprinted with permission. 
 
1.2. Neurobiology of schizophrenia 
Dopamine (DA) and glutamate are the two primary neurotransmitter systems most frequently 
implicated in the pathogenesis of SZ (Frohlich & Van Horn, 2013). There is a complex relationship 
between multiple neurotransmitter systems in SZ and there has been an ongoing attempt to 
disentangle their relative contributions, including the effects of gamma-Aminobutyric acid (GABA), 
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serotonin (5HT) and acetylcholine in generating the core symptoms of SZ (López-Gil, Artigas, & 
Adell, 2010).   
 
1.2.1 The dopamine theory of schizophrenia and antipsychotics 
Alterations in DA transmission are considered in all hypotheses about the aetiology and 
pathophysiology of SZ (Howes et al., 2012). This is due to the effects of antipsychotic drugs (APDs), 
that has been a cornerstone of SZ treatment since the 1950s, with the discovery of chlorpromazine 
(López-Muñoz et al., 2005). The D2 dopamine receptor (D2R) is a necessary component for the 
therapeutic action of virtually all APDs (Creese, Burt, & Snyder, 1976; Remington, 2003; P Seeman 
& Lee, 1975). This has held true for the first-generation (DA antagonism), the more recent second-
generation APDs (5HT2A/DA antagonism), as well as the new partial DA agonists (e.g., aripiprazole) 
(Abi-Dargham & Laruelle, 2005; Casey & Canal, 2017; B. L. Roth, Sheffler, & Kroeze, 2004). 
Studies using positron emission tomography (PET) imaging have shown patients with SZ have 
increased subcortical synaptic DA, increased [18F]DOPA uptake, and exhibit abnormally high DA 
release in response to an amphetamine challenge (Howes et al., 2012; L. Kegeles et al., 2006; L. S. 
Kegeles et al., 2010; Laruelle, 1998). The DA theory of aberrant salience provides an explanation for 
some of the positive delusional symptoms of psychosis due to overactive subcortical dopaminergic 
dysfunction, specifically presynaptic DA function in the associative striatum (Kapur, 2003; Kesby, 
Eyles, McGrath, & Scott, 2018; Philip Seeman & Kapur, 2000). In contrast, it has been suggested that 
an underactive DA system in the frontal cortex may underlie some of the cognitive and negative 
symptoms (Davis & Kahn, 1991; Moore, West, & Grace, 1999). 
 Psychostimulants, (e.g., amphetamine and cocaine) through increasing the availability of 
synaptic DA, can produce positive symptoms that resemble psychosis in humans and increase the 
locomotion response, a proxy measure for psychosis in animals (Bramness et al., 2012; Farnia & 
Golshani, 2016; Robinson & Becker, 1986). As reviewed by J. Lieberman, Kane, and Alvir (1987) 
74–78% of patients with SZ have intensified psychotic symptoms after being given amphetamine. 
Acute psychotic symptoms can also be elicited in healthy volunteers after a large single dose of 
amphetamine (Angrist & Gershon, 1970), however, at lower doses psychosis only emerges after 
repeated dosing in a small subset of ~25% of individuals (Bramness et al., 2012). In addition, positive 
symptoms induced by psychostimulants are ameliorated by APD treatment, although their efficacy in 
this regard has perhaps been overstated (C. Curran, Byrappa, & Mcbride, 2004; Janowsky, El-Yousef, 
Davis, & Sekerke, 1973; J. Lieberman et al., 1987; Philip Seeman, 2011).  
 Although approximately 30% of people respond to APDs and enter full remission, and a 
further 30% show a partial response, around 20-30% do not respond to these medications at all and 
are regarded as treatment-resistant (J. A. Lieberman et al., 2005; Meltzer, 1997; Mosolov, Potapov, & 
Ushakov, 2012; Steeds, Carhart-Harris, & Stone, 2015). Pertinently, APD resistance has been 
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associated with elevated cerebral glutamate levels, in the absence of dopaminergic abnormalities. This 
suggests that treatment-resistant patients do not respond to DA blocking medication because their 
illness is not primarily characterized by hyperdopaminergia (Demjaha et al., 2014; Mouchlianitis et 
al., 2015). Furthermore, even when patients do respond to treatment, current APDs show no clinical 
differences in efficacy and are primarily differentiated by their side effect profile (Abbott, 2010; J. A. 
Lieberman et al., 2005). Clozapine is an exception, but its clinical utility is restricted by the 
propensity to cause potentially fatal agranulocytosis and the requirement of mandatory hematologic 
monitoring (Alvir, Lieberman, Safferman, Schwimmer, & Schaaf, 1993; Kilian, Kerr, Lawrence, & 
Celermajer, 1999). Side-effects can be severe and debilitating, leading many patients to discontinue 
their medications, for example, extrapyramidal symptoms (e.g., tardive dyskinesia) are particularly 
problematic for first-generation APDs, and metabolic disorders that occasion dramatic weight gain for 
the second-generation (J. Geddes, Freemantle, Harrison, & Bebbington, 2000; Leucht et al., 2013; 
Leucht et al., 2017; J. M. Meyer, 2000). Troubling evidence has accumulated that chronic use of DA 
antagonists can result in brain atrophy, a contributing factor to poor outcomes (Fusar-Poli et al., 2013; 
Ho, Andreasen, Ziebell, Pierson, & Magnotta, 2011; Zipursky, Reilly, & Murray, 2012). 
 For those who do respond to medication, long term compliance is required with 
discontinuation of a medication usually resulting in a relapse (Boonstra, Burger, Grobbee, & Kahn, 
2011; Cerovecki et al., 2013; Moncrieff, 2006). Even when effective in reducing positive symptoms, 
blockade of DA is largely ineffective at treating negative and cognitive symptoms, and it is these 
domains that are the most important for determining long-term functional outcomes (Carbon & 
Correll, 2014; Fervaha, Foussias, Agid, & Remington, 2014; Leifker, Bowie, & Harvey, 2009). Sixty 
years after the discovery of the first antipsychotic, new therapeutic targets and a better understanding 
of the basic biological processes that drive pathogenesis are needed, in order to develop 1) novel 
therapeutics for treatment-resistant patients and 2) therapeutics that treat all three domains, with a 
minimum of side-effects (Carpenter & Koenig, 2008; Gray & Roth, 2007; Steeds et al., 2015).  
 
1.2.2 Evidence for a state of NMDA receptor hypofunction 
In the past six decades, abnormalities found in human subjects and the various animal models of SZ 
converge on the dysfunction of the N-methyl-D-aspartate glutamate receptor (NMDAR) as a central 
pathological hub in the aetiology of SZ. The glutamate hypothesis originated from the observation 
that the psychotomimetic drugs phencyclidine (PCP) and ketamine induce both negative and cognitive 
symptoms, as well as positive symptoms, by blocking neurotransmission at NMDAR (Frohlich & Van 
Horn, 2013; Lodge & Mercier, 2015; Moghaddam & Krystal, 2012; Olney & Farber, 1995). Multiple 
studies have shown that NMDAR hypofunction, in the limbic brain region, may underlie many 
aspects of molecular, cellular, and behavioural abnormalities associated with SZ (Ingram et al., 2018; 
Monyer, Burnashev, Laurie, Sakmann, & Seeburg, 1994; Tamminga, 1999). Post-mortem reports 
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have corroborated these clinical insights by detecting changes in, protein subunit expression, 
transcription, and receptor binding profiles in the prefrontal cortex (A. E. Geddes, Huang, & Newell, 
2011; Kristiansen, Beneyto, Haroutunian, & Meador-Woodruff, 2006), thalamus (Clinton, 
Haroutunian, & Meador‐Woodruff, 2006; Dracheva, Byne, Chin, & Haroutunian, 2008) and 
hippocampus (Beneyto, Kristiansen, Oni-Orisan, McCullumsmith, & Meador-Woodruff, 2007; Gao et 
al., 2000). Numerous SZ risk genes have been identified that regulate components of NMDAR 
mediated signalling (Harrison & Weinberger, 2005) critically involved in early brain development 
(Du Bois & Huang, 2007), epigenetic risk (Jaffe et al., 2016), neuroinflammation (Sekar et al., 2016), 
oxidative stress (Hardingham & Do, 2016), and synaptic plasticity (Lisman et al., 2008). Rodent 
genetic knockouts of cell-type selective NMDAR subunits have helped to further elucidate the central 
role of NMDAR hypofunction and the molecular/cellular determinants that produce SZ-related 
behavioural outcomes (Ingram et al., 2018; Nakazawa, Jeevakumar, & Nakao, 2017). Finally, patients 
with anti-NMDAR encephalitis, a synaptic autoimmune disorder, present early in the disease course, 
with classic SZ-like symptoms, including hearing voices and paranoia, and evidence that at least in 
some cases, immune mechanisms can be directly involved in the pathogenesis of psychosis (Dalmau, 
Lancaster, Martinez-Hernandez, Rosenfeld, & Balice-Gordon, 2011; Kayser & Dalmau, 2014). 
Moreover, glutamatergic neurons interact with other neurons, including morphologically altered 
GABAergic interneurons and reciprocal synaptic relations between forebrain dopamine projections, 
providing an account of other neurotransmitter systems that have been strongly implicated in the 
disorder (Jentsch & Roth, 1999; Kokkinou, Ashok, & Howes, 2018; Moghaddam, Adams, Verma, & 
Daly, 1997). Therefore, the NMDAR hypofunction model presents an account from the putative roles 
of SZ genes and environmental risk, to a comprehensive understanding of the disorder at the neural 
systems level, with a major advantage over other theories, in being able to account for all symptom 
domains and incorporate a multitude of schizophrenic risk factors. 
 
1.2.3 The glutamate synapse and schizophrenia 
Glutamate acts as the primary excitatory neurotransmitter in the mammalian brain, with glutamatergic 
neurons comprising 60-80% of total brain metabolic activity (Rothman, Behar, Hyder, & Shulman, 
2003). Approximately 60% of neurons contain glutamate, and virtually all of them have some type of 
glutamate receptor. Glutamatergic neurotransmission occurs through ionotropic (ligand-gated cation 
channels) and metabotropic (G-protein coupled) receptors. Ionotropic glutamate receptors include the 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and NMDA (Dingledine, 
Borges, Bowie, & Traynelis, 1999; Traynelis et al., 2010). NMDARs are tetraheteromeric assemblies 
usually composed of four subunits: two that bind the glycine (GluN1 subunits) and two that bind 
glutamate (GluN2 subunits) (Traynelis et al., 2010). The opening of the cation channel requires both 
concurrent binding of the co-agonist glutamate and glycine and membrane depolarisation, to remove 
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the Mg2+ block. As a result, the NMDA receptor can act as a molecular coincidence detector for pre- 
and postsynaptic activity, integrating and decoding incoming synaptic activity (Cull-Candy, Brickley, 
& Farrant, 2001; Malenka & Nicoll, 1993). High calcium permeability mediates many of the effects 
of NMDAR activity, including learning and memory, activity-dependent brain development, synaptic 
modification, and homeostatic neuro-protective/degenerate signalling (K. F. Bell & Hardingham, 
2011; Hardingham & Do, 2016; Paoletti, Bellone, & Zhou, 2013). The NMDA receptor is a prime 
target for pharmacotherapy due to its implications in SZ and central role in synaptic mediated 
plasticity. 
 
1.2.4 Ketamine: inhibition of the NMDA receptor 
Ketamine is a noncompetitive NMDAR antagonist (Anis, Berry, Burton, & Lodge, 1983) that requires 
an open NMDAR channel to antagonise (MacDonald et al., 1991). Along with its structural analogues 
phencyclidine (PCP) and MK-801, ketamine produces a trapping type of block, binding at a site deep 
within the ion channel, occluding the flow of ions, and remaining in the channel when closed 
(Huettner & Bean, 1988). This latter property can account for a long-lived block that is relieved by 
channel opening. Ketamine is less potent than PCP and MK-801 because of faster dissociation from 
the open channel (Johnson & Kotermanski, 2006). Ketamine’s effects on NMDARs appear to 
contribute significantly to a variety of dose-dependent psychoactive effects; anxiolytic and analgesia 
effects occur at low doses (Schmid, Sandler, & Katz, 1999; L.-M. Zhang et al., 2015), 
psychotomimetic and anti-depressant effects occur at medium doses (Ladarola et al., 2015; Lodge & 
Mercier, 2015), and finally high doses result in a state of sedation, amnesia, and anaesthesia (Kohrs & 
Durieux, 1998; Van, 1977). The psychotomimetic effects of ketamine are only observed at 
subanaesthetic doses (Abdallah, Sanacora, Duman, & Krystal, 2015), at brain concentrations in the 
low micromolar range, where ketamine inhibits a fraction of NMDARs (approx. <50%), leaving a 
significant percentage of NMDARs unblocked (Dravid et al., 2007; Hartvig et al., 1995). 
Psychotomimetic effects are not observed with anaesthetic doses that block a higher fraction of 
NMDARs. Moreover, subanaesthetic doses have been shown to increase extracellular glutamate 
levels in the prefrontal cortex, up to 200%, in contrast to the decreases observed with anaesthetic 
doses (Abdallah et al., 2018; Moghaddam et al., 1997). Although ketamine has secondary sites of 
action unrelated to blockade of NMDA glutamate receptors, psychotomimetic effects are attributed to 
occupancy of NMDA receptors (Stone et al., 2008) and persist despite blockade of DA D2R (Krystal 





Figure 1.2 NMDA receptor and binding sites of various neurotransmitters including glutamate and 
glycine. Mg2+, MK-801, ketamine and PCP act as noncompetitive antagonists whose binding sites 
are within the ion channel pore region. Reprinted from “The NMDA receptor complex as a therapeutic 
target in epilepsy: a review,” by M. Ghasemi and S. C. Schachter, 2011, Epilepsy & Behavior, Volume 






1.2.5 Ketamine and the dissociatives: comparisons with schizophrenia  
 
Figure 1.3 Ketamine identification and chemical structure. Reprinted from “Critical review of 
KETAMINE,” by 34th ECDD (4.3), 2006, World Health Organisation, page number 3-5. Copyright 
[2006] by World Health Organisation. Adapted with permission. 
 
PCP was originally synthesized and released by Parke–Davis pharmaceutical company in 1958 as a 
general anaesthetic (Chen, Ensor, Russell, & Bohner, 1959; Greifenstein, DeVault, Yoshitake, & 
Gajewski, 1958). The use of PCP for this purpose often resulted in emergence reactions, psychotic 
side effects as the patient regains consciousness. For this reason, ketamine, a compound with a lower 
affinity for the NMDAR than PCP was developed as a safer alternative (Domino, 2010; Morris & 
Wallach, 2014). Ketamine’s emergence reactions, which includes hallucinations, paranoia and 
agitation are less severe than PCP, yet severe enough to limit its utility as an anaesthetic (Greifenstein 
et al., 1958). Notably, ketamine emergence reactions are very rare in children, emergence reactions 
increase after the age of 16, a vulnerability which overlaps with the age of onset for psychosis 
frequently observed by clinicians (Frohlich & Van Horn, 2013; Meyers & Charles, 1978). 
 In a typical human psychogenic experiment, a low dose ketamine (0.3-0.7 mg/kg) infusion is 
administered. This dose produces psychoactive effects lasting for no longer than 90 min and a 
psychosis lasting ~30 min (C. Adler, Goldberg, Malhotra, Pickar, & Breier, 1998; Krystal et al., 1999; 
Krystal et al., 1994; Lahti, Koffel, LaPorte, & Tamminga, 1995; Lahti, Weiler, Tamara, Parwani, & 
Tamminga, 2001; Malhotra et al., 1997; Oranje et al., 2000). An anaesthetic dose of ketamine in 
humans is approximately 6.5-13 mg/kg intramuscular injection (IM), and higher doses are required to 
anaesthetize rats ~80-100 mg/kg intraperitoneal injection (IP) (Gelb, Morriss, Johnson, & Merry, 
2018; Kohrs & Durieux, 1998; Van, 1977). An effective dose for a rat can be estimated through 
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allometric scaling and comparisons to human data (including self-reports), dosing in rats requires 
roughly a 10-fold increase (Björkman & Redke, 2000; Riviere, Martin‐Jimenez, Sundlof, & Craigmill, 
1997). Time course studies suggest that the duration of ketamine effects is slightly shorter for rats, but 
similar to humans with an alpha phase lasting 45-60 minutes (De Vry & Jentzsch, 2003; Radford et 
al., 2017). 
 The symptomatic profile of acute ketamine administration or chronic ketamine abuse has a 
factor structure so similar to SZ to be diagnosed by experienced clinicians as such (Cheng et al., 2018; 
H. V. Curran & Monaghan, 2001; Xu et al., 2015). In healthy volunteers, ketamine produces the full 
spectrum of positive symptoms, including hallucinations and perceptual distortions, paranoid 
delusions, somaesthetic sensations, and disorganized thinking (Frohlich & Van Horn, 2016). The 
chief advantage of NMDAR antagonist models is the improvement over other models which do not 
adequately explain negative and cognitive symptoms (Stone, Morrison, & Pilowsky, 2007). Ketamine 
induces negative symptoms, including flattened affect, alogia and social withdrawal (C. Adler et al., 
1998; H. V. Curran & Monaghan, 2001; Krystal et al., 1999; Krystal et al., 1994; Malhotra et al., 
1997) and cognitive symptoms, manifested as impairments of episodic memory encoding and 
retrieval, working memory (Morgan & Curran, 2006) and the acquisition of new rule-based 
information (Krystal et al., 2000). Moreover, in SZ volunteer’s ketamine psychotomimesis can lead to 
relapse and/or exacerbation of pre-existing symptoms (C. M. Adler et al., 1999; Lahti et al., 1995; 
Lahti et al., 2001). Taken together, the above evidence provides strong support that a ketamine 
challenge models all three principal domains of SZ symptomatology. 
 Evidence supporting the construct validity of ketamine rodent models is supplied by the 
emergence of specific structural, molecular, and system-level markers that are shared in common with 
SZ patients (Frohlich & Van Horn, 2013; Ingram et al., 2018; Neill et al., 2010). These include 
alterations in circuit function, including impairments in prefrontal cortical activation  (Meyer-
Lindenberg et al., 2002; Weinberger, Berman, & Zec, 1986) and functional connectivity (Driesen et 
al., 2013; Lisman et al., 2008; Stephan, Baldeweg, & Friston, 2006), increased glutamate in the 
prefrontal cortex (Abdallah et al., 2018; Moghaddam et al., 1997), and increased DA release in the 
prefrontal cortex, striatum and nucleus accumbens (Kokkinou et al., 2018; Moghaddam et al., 1997). 
A decrease of mRNA expression of GAD67, and the number and/or morphological alterations of 
GABAergic parvalbumin-positive interneurons (PVI) has also been reported (Homayoun & 
Moghaddam, 2007; Lewis, Curley, Glausier, & Volk, 2012; Taylor & Tso, 2015). Finally, aberrant 
rhythmic activity, especially in gamma-band oscillations (Cunningham et al., 2006; Pinault, 2008; 
Rotaru, Lewis, & Gonzalez-Burgos, 2012; Uhlhaas & Singer, 2006) and impairments in aspects of 
sensory-evoked potentials (Näätänen & Kähkönen, 2009; Oranje et al., 2000; Umbricht, Koller, 
Vollenweider, & Schmid, 2002; Watson et al., 2009) also occur under ketamine. Taken together, these 
studies strongly support the assertion that acute or chronic application of ketamine works similarly in 





Figure 1.4 Brief timeline of ketamine. Reprinted from “Classics in Chemical Neuroscience: Ketamine,” 
by M. W. Tyler and S. J. Haggarty, 2017, Science, Volume [8 (6)], page number 1123. Copyright 
[2017] by ACS Publications. Reprinted with permission. 
 
1.3.1 Animal models of psychosis 
1.3.1 The key problem: modelling psychosis within an animal 
A key problem with modelling psychosis in animals is how to assess some of the core symptoms of 
psychosis which are considered uniquely human traits (DeLisi, 2001). Certainly, the primary 
difficulty in modelling SZ in rodents is their inability to self-report hallucinations, disordered 
thinking, and other core features of the disease, an evaluation necessary to confirm a diagnosis within 
humans (Powell & Miyakawa, 2006; Verdoux & van Os, 2002). By necessity, current animal models 
of psychosis have relied on indices of overt behaviour that have questionable relevance to the internal 
experience of psychosis.  
 
Psychostimulant-induced locomotion (Featherstone, Kapur, & Fletcher, 2007; Snyder, 1972), and 
deficits in prepulse inhibition (PPI) (N. R. Swerdlow & Light, 2016; N. R. Swerdlow, Weber, Qu, 
Light, & Braff, 2008) are the two most common behavioural assays of positive symptoms in animal 
models. These tests are widely used because they are simple to perform and quantify, but given 
current knowledge of neurobiology in SZ, it is debatable whether they are useful as primary measures 
of psychosis.   
1.3.1.1 Psychostimulant-induced locomotion 
Psychostimulants (e.g., amphetamine and cocaine) and NMDAR antagonists (e.g., ketamine, PCP and 
MK-801) increase DA release in striatal brain regions of both humans (Breier et al., 1997; Kokkinou 
et al., 2018)  and rats (Moghaddam et al., 1997; Robinson & Becker, 1986). Increased locomotion or 
stereotypic behaviour in response to a psychostimulant or NMDAR antagonist is a simple test to 
evaluate DA hyperactivity in subcortical regions thought to underlie the psychotic symptoms of SZ 
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(Gleason & Shannon, 1997; O’Neill & Shaw, 1999). Unfortunately, these overt motor behaviours are 
at best tangentially connected to the subjective state of psychosis, for example, clinical studies 
comparing activity levels in patients with bipolar disorder and SZ indicate that hyperactivity is a 
cardinal feature of mania in bipolar disorder, but not of SZ (Perry et al., 2010).  
 The critical problem with a locomotion behavioural assay, however, is an anatomical 
misalignment between the DA pathways involved in the behavioural outcome deemed important – 
motor behaviours driven by limbic DA (David, Sissaoui, & Abraini, 2004; Pijnenburg, Honig, Van 
der Heyden, & Van Rossum, 1976; Pijnenburg, Honig, & Van Rossum, 1975) and clinical evidence of 
psychosis in patients - DA hyperactivity in the associative striatum (David et al., 2004; Howes et al., 
2009; L. Kegeles et al., 2006). Moreover, the main rationale for using this behavioural assay is the 
high predictive validity that is found in screening APDs, virtually all of which are D2R antagonists 
(Bardin et al., 2007; Jones, Watson, & Fone, 2011). This, however, can be considered serendipitous, 
as systemic administration of amphetamine increases DA function in both the limbic striatum 
(locomotion) and associative striatum (positive symptoms), and systemically administered APDs 
antagonise D2 receptors throughout the brain. Therefore, psychostimulant-induced locomotion 
predicts APD efficacy via DA release in a parallel circuit - the limbic striatum, and not in the 
anatomical region of interest - the associative striatum (Kesby et al., 2018). Optimally, APDs need to 
be developed that diminish DA signalling preferentially in the associative, rather than the limbic 
striatum. As a preclinical drug screen, hyperlocomotion would fail to predict the efficacy of such a 
novel medication and furthermore would have failed to detect any previous therapeutic selective for 
DA efflux in the associative striatum (Kesby et al., 2018). 
1.3.1.2 Prepulse inhibition 
Measurement of the acoustic startle response, an involuntary contraction of the facial and skeletal 
muscles in response to an abrupt stimulus, is used to assess sensorimotor gating. A weak lead acoustic 
stimulus (prepulse) can inhibit the startling effects of a subsequent strong stimulus, this startle-
inhibiting effect of the prepulse is a phenomenon known as prepulse inhibition (PPI). Reduced PPI 
values are theorised to represent an inability to filter out unnecessary sensory information (Geyer, 
Krebs-Thomson, Braff, & Swerdlow, 2001; N. R. Swerdlow et al., 2008). 
 Decreased PPI is one of the most consistently observed neurological impairments in SZ, 
disrupted in approximately 69% of patients (N. R. Swerdlow & Light, 2018). PPI deficits also respond 
to APDs and nearly identical effects are found across-species including in rodents and humans 
(Forrest, Coto, & Siegel, 2014; N. R. Swerdlow et al., 2008). However, as a primary measure of 
psychosis, PPI has a number of limitations. PPI has been detected in a wide range of neurological 
disorders (N. R. Swerdlow et al., 2008), including “normal” populations and disorders where 
psychosis is rare e.g., Huntington’s disease (N. R. Swerdlow et al., 1995) and Obsessive-compulsive 
disorder (OCD) (Ahmari, Risbrough, Geyer, & Simpson, 2012; Hoenig, Hochrein, Quednow, Maier, 
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& Wagner, 2005). As an isolated measure, PPI is not a reliable diagnostic marker for SZ, failing to 
predict the clinical course, specific symptoms, and individual treatment responses (N. R. Swerdlow et 
al., 2008). Moreover, it is not clear whether PPI deficits correlate with psychotic symptoms, and 
symptomatic SZ patients can exhibit levels of PPI within the normal range (Braff, Swerdlow, & 
Geyer, 1999; N. R. Swerdlow & Light, 2018).  
 This lack of specificity means 1) there can be no prior justification for claiming an animal 
model exhibiting reduced PPI is a symptom of SZ, rather than, for example, OCD. Or conversely, 2) 
that an animal model is rejected based on “normal” PPI values, as that model may still accurately 
recreate important aspects of SZ biology. Similar criticisms can be applied to other behavioural 
measures of psychosis, including latent inhibition and conditioned avoidance (Forrest et al., 2014). A 
truly useful animal model of psychosis should fulfil at least two requirements: 1) an objective 
procedure that allows an animal to self-report its internal state, and 2) a means to determine whether 
this internal state is analogous, to an internal state that produces subjectively psychotic-like effects in 
humans.  
 
1.4.1 The Drug Discrimination paradigm 
1.4.1 The acquisition phase 
The drug discrimination paradigm can provide an objective measurement of an animal’s internal state 
by evaluating the control that an internal drug state exerts over behaviour (Bolin, Alcorn III, 
Reynolds, Lile, & Rush, 2016; Porter, Prus, & Overton, 2018; Solinas, Panlilio, Justinova, Yasar, & 
Goldberg, 2006). Drug discrimination is a paradigm where an organism learns to distinguish the 
pharmacological effects of a psychoactive drug from the absence of a drug or from noticeably distinct 
pharmacological effects produced by other drugs (Colpaert, 1999; Porter et al., 2018; Solinas et al., 
2006). For over 50 years, drug discrimination procedures have provided a highly selective tool for in 
vivo pharmacologic measures of behaviourally-active drugs, demonstrating differential responding 
according to dose, mechanism of action (e.g., dopaminergic or glutamatergic), pharmacology class 
(e.g., stimulant or dissociative), and structural chemistry (constitutional and stereoisomers, salts of 
isomers, etc…)(Brady & Balster, 1982; Brady, Balster, & May, 1982; Colpaert, 2003; Gauvin, 
Zimmermann, & Kallman, 2016; Oberlender & Nichols, 1988; I. P. Stolerman, Childs, Ford, & Grant, 
2011). A central appeal of the procedure is that the discriminative stimulus properties of a 
psychoactive drug are inherently subjective, rather than objective (Kamien, Bickel, Hughes, Higgins, 
& Smith, 1993; Kangas & Maguire, 2016; Kelly, Stoops, Perry, Prendergast, & Rush, 2003; C. 
Schuster & Johanson, 1988). This paradigm thus provides researchers with an empirically reliable 
method to investigate in nonverbal subjects subjective experiences that have often been considered 
too complex and too private to characterise (Kangas & Maguire, 2016; C. R. Schuster, Fischman, & 
Johanson, 1981). Moreover, drug discrimination studies are valuable not only because they allow the 
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experimenter to objectively evaluate the subjective effects of a psychoactive drug, but also because 
the paradigm opens up new possibilities for how certain factors - for example, the interaction between 
the physiological state of the organism and the nature and dose of the training drug - can influence 
behavioural responses (Colpaert, 1999; R. A. Glennon & R. Young, 2011; Kangas & Maguire, 2016). 
As a consequence, the adaptation of drug discriminations procedures opens up the possibility of 
investigating if the internal state of an animal model of SZ is similar to that of a drug-induced state, 
where that state produces subjectively SZ-like effects in humans, research that should further enable 
an improved understanding of the underlying neurobiology of psychotic disorders (Forrest et al., 
2014; Jones et al., 2011; Nestler & Hyman, 2010).  
  The differentiation of discriminable stimuli - the ability to identify and respond to differences 
among stimuli - is a principle concept in the psychology of learning and behaviour and the base for 
the drug discrimination method (R. A. Glennon & R. Young, 2011; Sutherland & Mackintosh, 2016). 
Impaired discrimination learning and the formation of inappropriate associations is recognized as a 
core feature underpinning many psychiatric illnesses (Di Chiara, 1999; A. M. Owen, Roberts, Hodges, 
& Robbins, 1993; Sahay, Wilson, & Hen, 2011), particularly the positive symptoms of SZ (Bleuler, 
1950; Hofer, Doby, Anderer, & Dantendorfer, 2001; Stephan et al., 2006). Subjects (animals, 
including humans) are considered to be able to discriminate between two (or more) different stimuli if 
they can be trained to respond in a distinct manner upon presentation of each stimulus. The greater the 
difference between two stimuli, the more likely the animal will be able to perform the appropriate 
response and thus distinguish between them (R. A. Glennon & R. Young, 2011).  
 Successive training sessions are required for a subject to learn to accurately identify the 
effects produced by a training drug and the dose of that drug (Colpaert, 1999; Overton, 1971; Solinas 
et al., 2006). This is usually achieved using operant or instrumental techniques. Operant behaviour is 
any behaviour whose frequency in the future is determined primarily by its history of consequences 
(Bouton, 2007; G. S. Reynolds, 1975; Staddon & Cerutti, 2003). For example, a hungry rat “operates” 
on its environment and is trained to press a lever in a chamber containing a speaker that emits a tone. 
Lever-presses in the presence of a tone lead to the delivery of a reinforcer, but lever-presses when 
there is no tone do not. In such a situation, the rat’s press of the lever, which is followed by 
reinforcement (i.e., consequence), will likely result in an increased probability of the animal pressing 
the lever in the future. If the subjects can learn to discriminate between these two conditions of tone 
and no tone, the tone is said to act as a discriminative stimulus (Delprato & Midgley, 1992; Michael, 
1980).  
An important term related to discrimination learning is ‘stimulus control’. A stimulus is said 
to gain control over the response when this response occurs only in the presence of the discriminative 
stimulus. Stimulus control can be thus defined as the degree to which a particular response occurs in 
the presence of the discriminative stimulus and a different response, or the withholding of a response, 
occurs to a different stimulus (Jenkins, 1965; Morse & Skinner, 1958). Subjects tend to discriminate 
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between like stimuli and respond to specific stimuli only. On occasions when a conditioned response 
is elicited by a stimulus that is similar but not identical to the original stimulus, this is termed stimulus 
generalization (Sutherland & Mackintosh, 2016).  
A large body of research has shown how animals are capable of discriminating exteroceptive 
cues – stimuli that come from animals’ external environments. External cues can take a multitude of 
forms and can include anything that is distinguishable by an animal’s CNS and sensory modalities 
including changes in odour, shape, light and tone (Spence, 1936; Sutherland & Mackintosh, 2016). In 
contrast, the subjective effects of psychoactive drugs function as internal cues through interoception, 
or the ability of a subject to perceive its own internal physiological state (Craig, 2002, 2003; Hölzl, 
Erasmus, & Möltner, 1996; Naqvi & Bechara, 2010). Thousands of drug discrimination studies have 
clearly demonstrated discrimination using an interoceptive stimulus can be acquired with a similar 
effectiveness to classic external stimuli (e.g. light and tone) by a wide variety of laboratory animals 
(including rodents, birds, and primates) as well as human subjects (Bolin et al., 2016; Colpaert, 1999; 
Overton, 1971). The internal stimuli of drugs arise from the pharmacological interactions between the 
drug-ligand and molecular targets (e.g., receptors and transporters) located throughout the CNS and/or 
peripheral nervous system (PNS) (Julien, 2013). Centrally acting drugs modulate the functional state 
of endogenous neurotransmitter systems that, in turn, temporarily alter the subject’s mood, thought, 
and behaviour (Holtzman & Locke, 1988). Since drugs differ in their primary mechanisms of action, 
i.e., selectivity for molecular targets, and relative potency of effect, these pharmacological actions can 
produce a range of distinct interoceptive stimuli that are readily discriminable (Colpaert, 1999; I. P. 
Stolerman et al., 2011). The current consensus within the literature is that the discriminative stimulus 
of psychoactive drugs is based entirely or at least to a significant degree upon their subjective effects 
(Bolin et al., 2016; C. Schuster & Johanson, 1988). This assertion is supported by drug discrimination 
studies that have been adapted for humans which are accompanied by validated procedures for 
quantifying and assessing the effects of psychoactive drugs by verbal subjective reports (Bolin et al., 
2016; Kamien et al., 1993; Preston & Bigelow, 1991). Reviews of human drug discrimination studies 
have revealed a high degree of concordance between the discriminative and subjective effects of a 
drug for a diverse range of pharmacological mechanisms, including opioids, stimulants and sedatives 
(Bolin et al., 2016; Oliveto, Bickel, Kamien, Hughes, & Higgins, 1994; Preston, Bigelow, Bickel, & 
Liebson, 1989; Rush, Vansickel, & Stoops, 2011). We do note that this relationship is complicated by 
the fact that drugs produce compound experiences, including a range of co-occurring internal 
sensations that vary across multiple dimensions, and the qualitative nature of self-reporting where 
interpretations are influenced by personal histories and experience (Bolin et al., 2016; Brauer, Goudie, 
& de Wit, 1997; C. Schuster & Johanson, 1988; C. R. Schuster et al., 1981). This suggests that drug 
discrimination provides a remarkably sensitive and accurate behavioural analogue in animals to what 
humans verbally report of subjective drug experience.  
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 In the drug discrimination procedure, the subjective/internal cues function to disambiguate a 
set of differential reinforcement contingencies (Bolin et al., 2016; R. A. Glennon & R. Young, 2011; 
Preston & Bigelow, 1991). For example, in a two-lever operant box, an animal is reinforced (e.g. by 
food pellets) for pressing the right lever after being injected with a central nervous system (CNS)-drug 
or pressing the left lever after injection with vehicle (R. A. Glennon & R. Young, 2011; McMahon, 
2015; Porter & Prus, 2018; Solinas et al., 2006) . Training is usually carried out in a single daily 
session with a fixed number of trials. For each trial within a session, a rat must complete a fixed ratio 
of responses (i.e., concurrent FR 10) on the drug-, or vehicle-appropriate lever, to trigger the delivery 
of a reinforcer (Solinas et al., 2006). Figure 1.5 shows hypothetical data depicting the acquisition of a 
two-lever drug discrimination task. At the beginning of training, animals tend to distribute the 
responses evenly between the drug and vehicle levers (R. A. Glennon & R. Young, 2011; Porter & 
Prus, 2018). As training continues the number of responses on the drug-lever increases during 
sessions preceded by a drug injection (black circles) and decreases during sessions that are preceded 
by a vehicle injection (white circles). 
 
 
Figure 1.5 Hypothetical drug discrimination data presenting the acquisition of a training drug as a 
discriminative stimulus. 
 
Since the delivery or non-delivery of a reinforcer may guide subsequent responding, only responding 
to the first reinforcer is exclusively controlled by the stimulus effects of the drug/vehicle injection. 
The remaining trials within a session effectively function as training to strengthen the learned 
association between the discriminative stimulus and the stimulus appropriate-lever (Colpaert, 2003; 
Colpaert, Niemegeers, & Janssen, 1976; R. A. Glennon & R. Young, 2011; Young, 2009). 
Accordingly, only the distribution of responses to the first reinforcer is used to determine whether the 
discrimination has been acquired. Training sessions continue until a predetermined acquisition 
18 
 
criterion has been met (i.e., accuracy ≥ 90%) and this criterion is maintained for a consecutive number 
of sessions (i.e., 5 sessions of ≥ 90% stimulus-appropriate responding), see methods section for details 
(McMahon, 2015; Solinas et al., 2006; I. P. Stolerman et al., 2011).  
 
1.4.2 The physiological state of the organism 
Drug discrimination studies on the subjective effects of drugs are valuable not only because they 
allow the experimenter to objectively evaluate the effects of a psychoactive drug, but also because the 
paradigm opens up new possibilities for how certain factors (i.e. training drug, dose, and the 
physiological state of the organism) can influence the discriminability of drug stimuli (F. C. Colpaert, 
1999; Glennon & Young, 2011; Kangas & Maguire, 2016). One of the first animal studies to 
investigate the influence that an animal's physiological state can have on the acquisition of a drug 
stimulus were carried out in the mid-1970s by Weissman (1976).  In this study, 12 of 24 rats were 
made arthritic by a single intradermal paw injection of Mycobacterium butyricum. Both groups of rats 
were then trained to discriminate aspirin suspended in saline (56 mg/kg) from saline alone. The 
healthy controls were unable to readily discriminate the aspirin cue, while, the arithmetic rats in the 
presence of chronic pain readily acquired the discrimination with a significantly higher discrimination 
accuracy in the last four (out of 8) blocks of training. Similarly, it has been found that antipsychotics 
such as haloperidol are difficult to discriminate at therapeutic doses because they lack distinct subject 
effects (McElroy, Stimmel, & O'Donnell, 1989). However, an animal that has been pre-treated with 
chronic amphetamines and then tested after a wash out period, can rapidly acquire haloperidol 
discrimination at small doses (Barrett & Steranka, 1983; Lal, 1979). The notion that the affective 
baseline conditions of subjects can influence the discriminative- stimulus response, is highlighted by 
the following example. Barry III and Krimmer (1979)  trained two groups of rats to discriminate the 
anxiolytic phenobarbital vs saline. One group received a food reward for correct discrimination, while 
the other group received a foot shock for an incorrect response. Following training, dose response 
sessions were conducted with multiple doses of each drug and generalisation tests with 
chlordiazepoxide and ethanol. The ED50 of phenobarbital for the food reward task was 5.2 mg/kg, 
whereas the shock avoidance paradigm engendered an ED50 of 2.5 mg/kg, lower ED50 values were 
also reflected in the generalisation of chlordiazepoxide. Ethanol failed to generalise for the food 
reward contingencies but ED50 values could be calculated for the shock avoidance contingencies. The 
researchers suggested that the two incentives produce psychologically opposing states and shock 
avoidance can be conceived of as anxiety induction. Therefore the common anxiolytic properties of 
phenobarbital, chlordiazepoxide and ethanol would be highly salient to anxious animals compared to 
their non-stressed counterparts as evidenced by the lower ED50 values and generalisation of ethanol 
(Barry III & Krimmer, 1979). Taken together, these results show that the discriminability of a drug 




1.4.3 The generalisation phase 
After discrimination of the training dose is established, a dose-effect curve can be constructed by 
testing a range of drug doses. The dose-effect curve acts as a psychophysical gradient in which the 
subjects indicate how they perceive similarities between the dose of a psychoactive drug given in test 
sessions and the dose of a psychoactive drug used for training (R. Glennon & R. Young, 2011; 
Solinas et al., 2006). If the test dose elicits responding on the drug-lever then it is assumed to share 
discriminative stimulus properties with the training dose (Brady & Balster, 1982; Solinas et al., 2006). 
The proportion of responses allocated on the drug lever acts as an index of generalization (i.e., partial 
vs. full). In cases where a test compound produces an intermediate proportion of drug-appropriate 
responding – approximately 40-70% – it is said to partially generalise to the training stimulus, 
indicating that the test dose produces a graded response that is somewhat similar or somewhat distinct 
to the training stimulus (Gauvin, Zimmermann, Code, & Baird, 2018; Solinas et al., 2006). An 
important observation from early drug discrimination experiments is that animals preferentially select 
the vehicle (inert) lever when administered a dose of a drug that is qualitatively distinct (distinct 
stimulus class) from the training dose. In other words, the vehicle lever is the default response in all 
conditions except for those which resemble subjective effects of the training drug condition. For 
example, Shannon and Holtzam (1977) trained animals to discriminate 3mg/kg morphine from saline 
and found that test doses between 3-100 mg/kg of mescaline – a drug with distinct subjective effects - 
produced a maximum of 100% vehicle-appropriate responding. Thus, the drug discrimination model 
may be best understood as the discrimination between the presence versus absence of the specific 
internal cue (i.e. psychotomimetic effects) of the training drug (Frey & Winter, 1978). 
  The subjective effects of ketamine are highly dose dependent with low, medium and high 
doses producing relatively distinct stimulus cues with differential responding (Oye, Paulsen, & 
Maurset, 1992; Rogers, Wise, Painter, Longe, & Tracey, 2004). The florid psychotomimetic effects 
are only apparent in the medium dose range when a threshold in steady state-plasma concentration is 
crossed (50–200 ng/ml, in humans), with lower doses typically producing analgesia and anxiolytic 
effects, and high doses amnesia and anaesthesia (Rogers et al., 2004; Schartner, Carhart-Harris, 
Barrett, Seth, & Muthukumaraswamy, 2017). Doses within the medium- psychotomimetic range is 
where ketamine imparts the greatest pharmacological selectivity and the most distinct subjective 
effects (Dakwar et al., 2014; Khlestova, Johnson, Krystal, & Lisman, 2016; Schartner et al., 2017). 
Similarly, to many other psychoactive drugs, ketamine lacks specificity at low doses, and will readily 
generalise to other classes. For example, animals trained to discriminate ethanol will recognise the 
ethanol-like properties of a low- dose NMDA antagonist, but animals trained to discriminate medium 
doses of ketamine will distinguish ethanol as a distinct type of drug (Grant & Colombo, 1993; Krystal 
et al., 1998; I. Stolerman, Mariathasan, & Garcha, 1991). At high doses, ketamine induces 
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dissociative stereotypy that can produce marked behaviour disruption such as circling and side to side 
head movement (head weave) accompanied by ataxia and ambulation; a further increase of dose leads 
to immobility and anaesthesia (Radford et al., 2017). 
   Qualitative differences between high and low doses have been observed with a number of 
training drugs (I. P. Stolerman et al., 2011). For example, rats trained with a low dose (1.5 mg/kg) of 
±3,4-methylenedioxymethamphetamine (MDMA) will more readily substitute for serotonin agonists 
compared to those trained with high doses (3.0 mg/kg). Conversely, DA agonists only partially 
substitute for a high dose of MDMA and not low doses (Harper, Langen, & Schenk, 2014). These 
results suggest that high vs low dose MDMA produces qualitatively distinct stimulus effects and the 
relative contributions at these doses of serotonin (entactogen) and DA (stimulant) may underlie this 
observed difference (Webster, Schenk, & Harper, 2015). Similarly, ketamine induces a complex 
stimulus cue, with alterations in brain concentrations involving the recruitment of different ratios of 
NMDAR subtypes, additional neurotransmitter systems (e.g. DA, cholinergic and opioid), and 
specific cell types (e.g. fast-spiking interneurons) (Kraguljac et al., 2017; Sleigh, Harvey, Voss, & 
Denny, 2014; Zorumski, Izumi, & Mennerick, 2016). In the current experiment, following acquisition 
of drug discrimination, ketamine doses were tested that either shared congruent psychotogenic effects 
or produce incongruent subjective effects – in other words, qualitatively distinct effects from 
psychosis (Kohrs & Durieux, 1998; Ladarola et al., 2015; Lodge & Mercier, 2015; Schmid et al., 
1999; L.-M. Zhang et al., 2015). This essentially allowed us to ask whether the dose of ketamine 
being tested produced subjective effects that are like the psychotogenic effects of the training dose. In 
the current experiment, psychotogenic ketamine doses were predicted to produce the maximal 
responses on the drug-appropriate-lever, with the prediction that any difference between groups (MIA 
vs control) would be specific to these doses. This allowed us to determine if any differences in MIA 
rat’s discrimination of ketamine were specifically related to the psychotomimetic effects, rather than, 
e.g., a decreased sensitivity to ketamine in general. 
 
 
Figure 1.6 Schematic representation of the Drug Discrimination training and testing procedures. 
Reprinted from “Using drug-discrimination techniques to study the abuse-related effects of 
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psychoactive drugs in rats,” by M. Solinas and S. R. Goldberg, 2006, Nature Protocols, Volume (1), 
page number 1194. Copyright [2006] by Nature Publishing Group. Reprinted with permission. 
 
  
   
 
1.4.4 A behavioural marker of internal states 
The previous studies illustrate how the influence of internally produced discriminable stimuli is not 
limited to drugs alone. Rather, the discriminative stimulus is an interface between the drug’s effects 
and the physiology of the organism being tested (Barry III & Krimmer, 1979; Kangas & Maguire, 
2016; Lal, 1979; Weissman, 1976). In the current experiment a 7.5 mg/kg dose of ketamine was 
specifically selected for training since it is known to be both readily discriminable and to be an 
analogous dose in rats to those that produce effects that mimic psychosis in humans (Chiamulera, 
Armani, Mutti, & Fattore, 2016; De Vry & Jentzsch, 2003; Zanos et al., 2016). By establishing the 
subjective effects of ketamine as a cue for a specific behavioural response, i.e., stimulus-appropriate 
lever press, the rat’s response effectively permits an experimenter to determine if a drug effect i.e., a 
psychotomimetic dose of ketamine, has been perceived (Brady & Balster, 1982; Colpaert, 1999; 
Young, 2009). Dose-response effects were further evaluated by substituting test doses of ketamine 
that were either predicted to induce psychotic-stimulus effects similar to the training dose, or 
psychoactive effects not typically characterised as psychosis (Imre, Fokkema, Den Boer, & Ter Horst, 
2006; Oye et al., 1992; I. P. Stolerman et al., 2011; Zorumski et al., 2016). Finally, controls were 
performed to rule out other potential confounds resulting from MIA treatment, including an impaired 
ability to learn the drug discrimination task, a decreased sensitivity to ketamine, or a general 
decreased sensitivity to internal states (Corwin, Woolverton, & Schuster, 1990; R. A. Glennon & R. 
Young, 2011; Porter & Prus, 2018; Solinas et al., 2006). By comparing the performance of MIA rats 
in ketamine discrimination to matched control, we can attempt to objectively evaluate the similarity of 
the drug’s effects, to the MIA animal’s subjective state. Failure of drug discrimination occurs when 
the subjective state produced by the drug is not sufficiently different from the animal’s baseline 
physiological state (Colpaert, 1999; Overton, 1984; Solinas et al., 2006).  We hypothesised that if the 
internal state of the MIA rats is similar to psychosis it should manifest as 1) slower acquisition of the 






















Animals were generated following the protocol as described previously by D. D. Dickerson, Wolff, 
and Bilkey (2010). Eighteen Female Sprague-Dawley rats (Hercus Taieri Resource Unit Dunedin, 
New Zealand) were mated at three months of age. On gestational day 15 (GD15), under isoflurane 
anaesthesia, experimental dams were administered a single dose of Poly I:C (4.0 mg/kg i.v.; Sigma-
Aldrich, Auckland, New Zealand) dissolved in saline, while control dams received the equivalent 
saline injection. Dams were monitored 24hrs after injection and weighed throughout the pregnancy. 
Litters were culled to six males, i.e. three Poly I.C. and three saline offspring. Once weaned on 
postpartum day 21 (see, figure 2.1.), litters were group housed in standard plastic bottom/wire lid 
cages, three males per cage, based on treatment group (until at least three months old). The 42 animals 
used in this experiment (21 MIA and 21 control) were obtained from independent litters and dams. 
Animals were prepulse inhibition (PPI) tested from ∼3 months of age. Commercial rat pellets were 
rationed by adjusting post-session feedings to maintain body weights above 85% of free-feeding 
weights. Animals were housed in either separate or paired standard cages measuring 23 x 34 cm wide 
x 27 cm high and 52 x 34 cm wide x 27 cm high, respectively, with a plastic bottom/wire lid. In a 
colony room maintained on a 12 light (7:00-19:00)/12h dark cycle and kept in temperatures (22 °C ± 
1 °C), with water available ad libitum in their home cages. All testing procedures were in accordance 
with guidelines published for the University of Otago Code of Ethical Conduct for the Manipulation 




2.2 Operant chambers   
All experiments reported here were conducted using 10 identical operant chambers (Med-associates, 
St. Albans, VT: model ENV-008w) with internal dimensions of 30.5cm (length) x 24.1cm (width) x 
21.0cm (height). One wall of each chamber consisted of cue lights located above two retractable 
levers and a food hopper centred between them. An automatic food dispenser was used to deliver 45-
mg food pellet reward (Bio-serv, Flemington, NJ). The opposite wall contained a house light, which 
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provided chamber illumination, and a speaker, which presented tones to signal reward delivery (90dB, 
2500Hz, 250ms). Head entries into the food hopper were recorded using an infrared photocell 
detector. Ambient noise was attenuated by a fan, which produced 72dB white noise. Chambers were 
situated in individual cupboards to block ambient light and restrict external noise. Experimental 
events were programmed, and data were recorded using MedPC IV.  
 
 
2.3 Prepulse inhibition  
Impaired sensorimotor gating of the acoustic startle response is a deficit found in patients with SZ 
(Weiss & Feldon, 2001). PPI is the reduction of startle response to a strong stimulus (the pulse) 
preceded by a weak acoustic stimulus (the prepulse) (N. R. Swerdlow, Braff, & Geyer, 2000). 
Assessment of PPI and acoustic startle responses were conducted in a sound-attenuated startle 
chamber, containing a light and fan (SR Lab; San Diego Instruments), following the protocol 
described previously in Wolff and Bilkey (2008, 2010). Animals were placed inside a Plexiglas 
holding cylinder (8.9cm in diameter) onto a platform mounted with a piezoelectric accelerometer. A 
computer running SR lab software delivered the acoustic stimuli through a speaker within the 
chamber. Each session began with a 5min acclimation period in which only background noise was 
present (68 dBA); the animals were next presented with 11 startle only trials (not used in the 
assessment of PPI). Testing consisted of six blocks of 10 trial types, with each trial type presented 
once per block, in a pseudorandom counterbalanced order. The 10 trials involved startle-only (120 
dBA, 40 ms), no stimulus (68 dBA background only), prepulse-only (72, 76, 80, and 84 dBA, 20 ms), 
and prepulse plus startle (at all prepulse intensities). A block of ten startle-only trials ended the 
procedure. The delay between prepulse and startle stimuli was held constant at 100 ms, and inter-trial 
intervals ranged between 8 and 23 s. Each session lasted ∼35 min. 
 
 
2.4 Drug treatment 
(+)- Ketamine hydrochloride (HCL) 100mg/ml and Morphine HCL 10mg/ml were obtained from 
Drug Control Office (Otago University, New Zealand). Ketamine HCL was diluted in 0.9% 
physiological saline to 25mg/ml. Saline vehicle and all other experimental supplies were obtained 
from standard commercial sources. Injections were administered intraperitoneally (IP), with an 
injection volume of 1ml/kg. All injections were given IP 15 min before the start of behavioural testing 





2.5 Operant procedures 
All experimental sessions took place once daily, at the same time each day. All training and testing 
took place during the light cycle. Each rat was assigned to a specific operant chamber for the entirety 
of the experiment, including all training and test sessions. At the end of each session, rats were 
returned to their home cage. Operant chambers and open field were cleaned between sessions with 
FLOSC sanitiser 0.25% to prevent the interference of olfactory cues (Extance & Goudie, 1981). 
After PPI testing and initial lever-press training, the operant and ketamine locomotion experiments 
began when the rats were ~3 ½ months of age. A cohort of 20 animals was consecutively tested on 
satiety discrimination, ketamine discrimination and dose-effect procedures. For the morphine 
discrimination and ketamine locomotion separate cohorts of 12, and 10 drug-naive animals were used, 
respectively. Figure 2.1 shows the experimental timeline for the study. 
 
 
2.5.1 Lever-press training 
Prior to training for two consecutive days, rats were exposed to the reinforcement pellets (10-20 
grams) in their home cage, to accustom the rats to eating pellets that were used during the experiment.  
2.5.1.1 Pellet training 
Rats were trained to retrieve pellets from the hopper over two sessions. Pellets were delivered on a 
variable interval schedule, with a mean interfood interval of ~30 sec. The session ended after 60 food 
pellets had been delivered. After two sessions of training rats were retrieving at least 55 of 60 pellets. 
2.5.1.2 Lever-press training - fixed ratio 10 
First, the rats were trained to associate a lever-press with the delivery of a reward. On each trial, either 
the left or the right lever was presented in a pseudo-random order. If the rat pressed the lever within 
10 secs this resulted in the delivery of a reward. If the lever was not pressed within 10 secs the lever 
was retracted and the next trial began. The criterion for progressing to the next stage of training was 
met when rats were lever-pressing on more than 80% of the 60 trials. This was achieved by most rats 
after two sessions of testing. For five rats that did not meet this criterion, an overnight (8-hr) training 
session was given. 
The next sessions began with both levers present. Initially, the rats were trained on a fixed-
ratio (FR) 5 schedule in which five presses on the designated lever resulted in the delivery of a food 
pellet. Rats received two sessions of this procedure. On each session, either the left or the right lever 
was designated as active or inactive. Responses on the active lever fulfilled the FR requirement, while 
responses on the inactive lever reset the requirement. Following two sessions of FR 5 training, the 
schedule was then increased to FR 10 (again with one session where each lever was designated as 
active). The session ended when 15 mins had elapsed. Once all rats acquired responding on FR 10, the 





2.5.2 Satiety discrimination  
A prefeeding challenge was administered to compare the sensitivity of MIA and control rats to an 
internal cue that was unrelated to psychosis (Carr, 2007; Corwin et al., 1990). The session began with 
one lever presented, the presentation of either the left or right levers were counterbalanced between 
rats and reinforced on FR10. In the initial phase, three consecutive days of lever-pressing to reward 
was collected as a baseline. On the fourth day, one hour before testing a pre-feeding challenge of 20 




2.5.3 Ketamine discrimination 
Drug Discrimination is a paradigm in which an animal can learn to discriminate the effects of a drug 
and report its presence by a behavioural response, i.e., lever pressing to obtain a reward (Solinas et al., 
2006). At the beginning of the experiment, the 20 animals were drug naïve. Each animal received 
either 7.5 mg/kg ketamine or saline, seven-days a week. Immediately after injection, the animals were 
placed in a darkened operant chamber for the duration of a 15-min pre-testing interval. After the pre-
testing interval had elapsed, the house light was illuminated, and levers extended, signalling the start 
of the session. FR 10 responses on the Drug (D)-appropriate lever resulted in food reward on 
ketamine sessions, or the Saline (S)-appropriate lever on saline sessions. Responses on the incorrect 
lever reset the FR contingency for reinforced responding on the correct lever. To account for possible 
position preference effects the D-S/left-right lever was counterbalanced between individual rats. The 
testing ended after 60 trials had been completed, or 15 mins had elapsed. The following 
considerations were applied to the sequence in which the D and saline S sessions were administered 
1) D and S sessions occurred equally as often, 2) simple alteration of D and S was avoided; 3) chains 
of consecutive D and S sessions could occur, with a maximum of three. A pseudo-random schedule 
was used of 1) D-S-S-D-S, S-D-D-S-S, S-D-S-D-D, D-S-D-S-D and 2) S-D-D-S-S, D-S-D-S-D, D-S-
S-D-D-, S-D-S-D-S. Rats with even serial numbers were initially run on schedule 1) and the others on 
schedule 2), with the sequence schedules reversed after 20 days (Colpaert, Niemegeers, & Janssen, 
1977). Criteria for discrimination was considered reached when control and MIA, 1) completed the 
first FR10 and 2) demonstrated greater than 90% stimulus-appropriate lever press responding to the 
first reward, for five consecutive sessions (Solinas et al., 2006). Fifty daily sessions were run. Each 




2.5.4 Dose-effect sessions 
Following the acquisition of drug discrimination, a dose-response function was determined. Sessions 
were run as explained previously, with the following exceptions. Doses of ketamine were chosen to 
produce a range of distinct psychoactive effects; from anxiolytic effects to sedation and amnesia 
(Brady & Balster, 1982). Sessions were run from Monday-Friday. Test sessions were conducted twice 
per week with ketamine injections of 1mg/kg, 3mg/kg, 10mg/kg, and 30mg/kg, or an equivalent 
volume of saline. The intervening sessions consisted of baseline sessions with the training dose or 
vehicle, to maintain stimulus control. The schedule was based on a two-week cycle with tests on 
Tuesdays and Fridays (i.e., DTVDT VTDVT). On Monday, baseline behaviour was re-assessed to 
evaluate any potential changes in behaviour, due to increased dose exposure (Solinas et al., 2006). All 
drug doses were tested four times in each animal; one determination was preceded by a D training day 
and the second determination was preceded by an S training day. The order in which the different 
drugs were given to each animal was randomized. Approximately half the animals received the doses 
in ascending order and half received the doses in descending order. All doses of the drug were 
administered to a given animal before testing the next determination.  
 
 
2.5.5 Morphine Discrimination 
Sessions were run as explained in drug discrimination training, with the following exceptions. Each 
animal received either 3.2 mg/kg morphine or saline. Thirty daily sessions were run. 
 
 
2.5.6 Ketamine Locomotion 
Open field tests were performed in order to compare the dose-response sensitivity of 1, 3, 10 and 30 
mg/kg ketamine on locomotion. Rats were placed in the centre of the field (a square box of 59 × 60 × 
21 cm) and observed for 45 min, post 15 mins saline or ketamine injection (i.p.). Each test was 
performed consecutively, once per day, seven days per week. All drug doses were tested twice in each 
animal. One determination was preceded by a ketamine challenge and the second determination was 
preceded by saline injection. The order in which the different drugs were given to each animal was 
randomized. Approximately half the animals received the doses in ascending order and half received 
the doses in descending order (Imre et al., 2006). Locomotor behaviour was recorded with a video 
tracking system (EthoVision, 1.96, Noldus Information Technology, Wageningen, The Netherlands). 






Figure 2.1 Experimental timeline and summary of procedures 
 
2.6 Data Analysis  
2.6.1 Prepulse inhibition 
Two-way repeated measures analysis of variance (ANOVA) were performed with treatment group as 
the between-subjects variable and prepulse intensity as repeated measures variables. Prepulse 
inhibition is expressed as % PPI, and was calculated using the formula: 
 
[100 − (PP/S) × 100] 
 
Where PP is the average response on prepulse+startle trials, and S is the average response on startle-
only trials. For each animal, raw startle values that were more than three standard deviations from the 
mean of the remaining trials were removed before % PPI was calculated. Post hoc Bonferroni 
corrected t-tests (two-tailed) were conducted to determine differences between treatment groups at 
specific prepulse intensities. Data are reported as group means with standard error of the mean. The 





2.6.2 Operant procedures 
The percentage of stimulus- and drug-appropriate responses, and response rates (responses/sec) were 
recorded for each experiment. Because the delivery or non-delivery of a reinforcer within a session 
may guide subsequent responding, discrimination accuracy was calculated as the number of correct 
responses as a percentage of the total responses to the first reward.  
 
Full substitution was defined as greater than or equal to 85% lever presses that occurred on the lever 
associated with the training drug. Partial substitution was defined as greater than or equal to 25% and 
less than 85% lever presses on the training drug lever. Less than 25% lever presses on the drug-paired 
lever were defined as no substitution (Solinas et al., 2006).  
 
Occasionally, no reinforcers were earned during the session, particularly during sessions preceded by 
a larger dose of ketamine. If a rat did not earn a reward (i.e. missing value) their lever selection data 
were excluded from data analysis.  
 
Results were analysed by two-way repeated measures ANOVA with the appropriate factors. Pearson’s 
product moment correlative analyses compared the mean ketamine discrimination accuracy and the 
mean % PPI scores. T-tests (two-tailed) were conducted to determine differences between treatment 
groups and response rates, post hoc Bonferroni corrections were applied when appropriate. Data are 
reported as group means with standard error of the mean. The significance level was set at P < 0.05. 
 
2.6.3 Ketamine Locomotion 
Hyperlocomotion evoked by ketamine was calculated by the difference in the total distance moved 
between 1, 3, 10 and 30 mg/kg ketamine and saline control tests. Two-way repeated measures 
ANOVA were performed with treatment group as the between-subjects variable and dose as repeated 
measures variables. Bonferroni corrections were applied for t-tests (two tail) when comparing 












3.1 Prepulse inhibition  
To determine if there was a deficit in sensory-motor gating after exposure to MIA treatment, we tested 
the rats on a PPI assay. Initially, we evaluated the animal’s responses to startle-only and pulse-only 
trials, to test for factors that could modulate PPI independent of the CNS, for example, impaired 
auditory acuity and mobility. An independent-samples t-test of startle-only trials yielded no 
significant group differences in startle between control (M = 1384.9, SEM = 144.8) and MIA (M = 
1433.0, SEM = 258.3), t(18) = -0.16, p = .873. A two-way repeated measures ANOVA, with startle 
reactivity on prepulse-only trials as the within subjects and group as the between subjects factors, 
revealed no significant group effect, F(1,18) = 0.32, p < .582. There was also no effect of prepulse 
intensity, (F(3,54) = 0.13, p < .945), and no significant effect of treatment x prepulse intensity, 
F(3,54) = 0.41, p > .747.  
 Figure 3.1 displays the percentage of PPI data as a function of the decibel level. For the 
purposes of the main analysis, we conducted a separate two-way repeated measures ANOVA, with 
prepulse intensity as the within subjects and group as the between subjects factors. The analysis 
revealed a significant group effect, with MIA rats displaying a deficit in % PPI compared to control, 
F(1,18) = 4.91, p < .04. There was also a significant effect of prepulse intensity, F(3,54) = 26.6, p < 
.001. There was no significant effect of treatment x prepulse intensity, (F(3,54) = .579, p > .631), 
indicating that for both groups % PPI increased with prepulse intensity. Bonferroni post-hoc analysis 
for each dBA revealed control and MIA offspring were significantly different at the 72dBA prepulse 
intensity (t(18) = 2.57, p < .05), with MIA animals displaying reduced PPI compare to controls. In 
summary, the difference in the startle response was modulated by the prepulse decibel intensity and as 
the prepulse became more salient % PPI increased. MIA rats displayed an overall impairment in % 
PPI that was not due to impaired auditory function or mobility, as indicated by the animals’ normal 
responses on startle-only and prepulse-only trials. The reduction in % PPI was particularly apparent 




Figure 3.1 The effect of MIA on % PPI in MIA and control offspring. Values represent mean % PPI on 
the y-axis; 72, 26, 80 and 84dBA prepulse intensities on the x-axis, with error bars indicating the 
standard error of the mean. Control N = 10 (closed blue bars), MIA N = 10 (closed red bars). *p < .05. 
 
 
3.2 Ketamine discrimination training 
Figure 3.2.1 plots the performance of control and MIA offspring during training to discriminate 7.5 
mg/kg ketamine from saline. Control rats successfully learned the discrimination by achieving 
stimulus control ≥ 90% at block seven of training and achieved the highest average across training (M 
= 94.1, SEM = 1.27). By comparison, MIA improved in discrimination over sessions but remained 
below criteria, peaking in block eight of training (M = 81.8, SEM = 3.42). To investigate whether 
control and MIA had statistically different performances during discrimination training a two-way 
repeated ANOVA was conducted, with training block as the within-subjects and group as the 
between-subjects factors. The analysis revealed a significant group effect (F(1,18) = 26.9, p = .001), 
with control displaying an overall higher discrimination accuracy compared to MIA rats. There was a 
significant effect of training block (F(9,162) = 17.3, p < .001), and no effect of block x group 
F(9,162) = 1.13, p > .343, indicating as training progressed the percentage of correct responses 
increased for both groups. Overall, both groups acquired a discrimination accuracy well above what 
would be expected by chance. MIA rats displayed a lower level of accuracy compared to their control 
counterparts. Control achieved the discrimination criteria at block seven and maintained a 





Figure 3.2.1 Percentage correct stimulus-appropriate responding for control and MIA offspring trained 
to discriminate ketamine (7.5 mg/kg) from saline. Values represent the percentage of correct stimulus-
appropriate responses before the first reward on the y-axis; each day value represents the average of 
five days on the x-axis, with error bars indicating the standard error of the mean. Control N = 10 




Figure 3.2.2 plots the interresponse interval, a measurement of the elapsed time between two 
successive lever-presses, for control and MIA offspring. Interresponse intervals were evaluated to rule 
out the possibility of MIA-induced behavioural disruption contributing to a deficit in ketamine 
discrimination. A two-way repeated measures ANOVA was conducted to analyse the training data, 
with training block as the within subjects and group as the between subjects factors. Analysis revealed 
no group effect, F(1,18) = 0.162, p > .692. A significant effect of training block, F(9,162) = 2.14, p < 
.029, with no significant effect of training block x group (F(9,162) = 0.71, p > .699), indicating that as 




Figure 3.2.2 The interresponse interval for control and MIA offspring trained to discriminate ketamine 
(7.5 mg/kg) from saline. Values represent the number of lever-presses per second before the first 
reward on the y-axis; each day value represents the average of five days on the x-axis, with error bars 






Figure 3.3.1 displays the percentage of responses by control and MIA offspring on the drug-
appropriate lever after substituting ketamine (1, 3, 10 and 30 mg/kg) for the training dose. In order to 
assess if there were dose-dependent differences in discriminating ketamine between control and MIA, 
a two-way repeated ANOVA was conducted with dose as the within subjects and group as the 
between subjects factors. The analysis yielded a significant group difference, F(1,18) = 16.55, p < 
.001), with control achieving a higher response accuracy compared to MIA. A significant effect of 
ketamine dose, F(3,54) = 66.9, p < .001 was also found. There was also a significant group x dose 
interaction, F(3,54) = 6.93, p < .001, indicating as the dose increased the percentage of correct 
responses to the ketamine cue differed between groups. Bonferroni post-hoc analysis for each dose 
revealed MIA and control offspring were significantly different at 3 (t(18) = 5.48, p < .001) and 
10mg/kg (t(18) = 2.69, p < .0352) and were not significantly different at 1 (t(18) = 0.145, p > .999) 
and 30 mg/kg (t(18) = 0.105, p > .999). To summarise, MIA performed with impaired accuracy only at 
a dose of ketamine that can induce a psychotomimetic cue (3 and 10 mg/kg). No difference was found 
between control and MIA for 1 and 30 mg/kg, doses of ketamine that are associated with qualitatively 




Figure 3.3.1 Dose-effect functions for the percentage of correct drug-appropriate responses after 
substituting a range of ketamine doses (1, 3, 10, and 30 mg/kg) for the training dose (ketamine 7.5 
mg/kg) in control and MIA offspring. Values represent the percentage of correct drug-appropriate 
responses before the first reward on the y-axis; ketamine 1, 3, 10, and 30 mg/kg dose on the x-axis, 
with error bars indicating the standard error of the mean. Control N = 10 (closed blue squares), MIA N 




Figure 3.3.2 plots the interresponse interval between lever-presses during the dose-effect sessions for 
control and MIA offspring. Ketamine, particularly at higher doses (i.e., 30mg/kg), can induce 
dissociative stereotypy, behaviours that can disrupt an animal’s ability to perform the task such as 
circling, head rocking and ataxia. Interresponse intervals were evaluated to determine if any of the 
doses of ketamine used produced significant behavioural disruption (Radford et al., 2017). A two-way 
repeated measures ANOVA was conducted with dose as the within subjects and group as the between 
subjects factors. Analysis revealed no group effect, F(1,18) = .411, p > 0.53. A significant effect of 
training block (F(3,54) = 26.72, p < 0.001), and no dose x group interaction (F(3,54) = .215, p > 
.885), indicating that as the dose increased the interresponse interval increased for both groups. A 
paired-samples t-test was conducted to compare the 10 and 30 mg/kg doses as there was a sharp 
increase in the interresponse interval at the highest dose of ketamine for both groups. Analysis yielded 
a significant difference in the interresponse interval between the 10 mg/kg (M= 2.66, SEM= 0.78) and 





Figure 3.3.2 Dose-effect functions for the interresponse interval after substituting a range of ketamine 
doses (1, 3, 10, and 30 mg/kg) for the training dose (ketamine 7.5 mg/kg) in control and MIA offspring. 
Values represent the average interresponse interval per second before the first reward on the y-axis; 
1, 3, 10 and 30 mg/kg doses on the x-axis, with error bars indicating the standard error of the mean. 
Control N = 10 (Drug: closed green circle, Vehicle: closed orange circle), MIA N = 10 (Drug: closed 




3.4 Satiety discrimination 
Figure 3.4 displays the percentage of lever-presses to food reward after pre-feeding. An independent-
samples t-test revealed there were no statistically significant differences in lever-presses between 
control (M = 41.2, SEM = 6.74) and MIA (M = 37.5, SEM = 3.55), t(15) = -0.417, p = .682. These 
results show that the prenatal poly I.C. treatment had no effect on modulating the “subjective” state of 
satiety and both groups showed a reduction in lever-presses after pre-feeding; a “normal" predicted 




Figure 3.4 Percentage of lever-presses after pre-feeding for control and MIA offspring. Values 
represent lever-presses to food reward after pre-feeding on the y-axis; and group on the x-axis, with 
error bars indicating the standard error of the mean. Control N = 10 (closed blue bars), MIA N = 10 






3.5 Morphine discrimination  
Figure 3.5.1 plots the performance of control and MIA offspring during training to discriminate 3.2 
mg/kg morphine from saline. Both control (M = 92.6, SEM = 2.49) and MIA (M = 92.8, SEM = 2.5) 
rats successfully learned the discrimination by achieving stimulus control ≥ 90% in block five of 
training, with no apparent differences between groups. To confirm the impressions of the figure, a 
two-way repeated ANOVA was conducted, with training block as the within-subjects and group as the 
between-subjects factors. Analysis revealed no group effect, F(1,10) = 0.014, p > = .909. A significant 
effect of training block, F(4,40) = 31.0, p < .001. The lack of a significant training block x group 
interaction (F(4,40) = 20.4, p > .948) indicates as training progressed the percentage of correct 
responses increased for both groups. In contrast to the ketamine discrimination, MIA treatment had no 
effect on the discrimination of a morphine stimulus, and both groups readily acquired the morphine 




Figure 3.5.1 Percentage correct stimulus-appropriate responding for control and MIA offspring trained 
to discriminate morphine (3.2 mg/kg) from saline. Values represent the percentage of correct 
stimulus-appropriate responses before the first reward on the y-axis; each day value represents the 
average of five days on the x-axis, with error bars indicating the standard error of the mean. Control N 




Figure 3.5.2 plots the interresponse interval between lever-presses during morphine discrimination 
training for control and MIA offspring. A two-way repeated measures ANOVA was conducted to 
analyse the training data, with training block as the within subjects and group as the between subjects 
factors. Analysis revealed no group effect, F(1,10) = 0.00, p > 0.991. A significant effect of training 
block, F(4,40) = 5.75, p < 0.001. With no effect of training block x group, (F(4,40) = 0.89, p > .479), 
confirming that there was no difference between groups and as training progressed the interresponse 




Figure 3.5.2 The interresponse interval for control and MIA offspring trained to discriminate morphine 
(7.5 mg/kg) from saline. Values represent the number of lever-presses per second before the first 
reward on the y-axis; each day value represents the average of five days on the x-axis, with error bars 




3.6 Ketamine locomotion   
Rats were tested on a locomotion assay, to determine if there were any dose-dependent differences 
between control and MIA to the sensitivity of ketamine evoked locomotion. Figure 3.6 plots the 
distanced moved for both control and MIA between ketamine (1, 3, 10, and 30 mg/kg) and saline 
control tests. A two-way repeated-measures ANOVA was conducted to analyse the locomotion data 
with dose as the within subjects and group as the between subjects factors. The analysis yielded a 
significant group difference, F(1,8) = 8.33, p < .02, with ketamine producing a larger increase in 
stimulated locomotion for MIA rats over all doses. No significant effect of ketamine dose, F(3,24) = 
3.97, p < .081 and no significant group x dose interaction, F(3,24) = .001, p < .975 were found. The 
difference between groups was most apparent at doses of ketamine that induce a psychotomimetic cue 
(3 and 10 mg/kg), with MIA rats displaying a larger increase in ketamine evoked locomotion. 
Bonferroni post-hoc analysis for each dose revealed MIA and control offspring were significantly 
different at 3 (t(8) = 4.16, p < .003) and 10mg/kg (t(8) = 2.87, p < .021) and were not significantly 
different at 1 (t(8) = 1.27, p > .241) and 30 mg/kg (t(8) = 0.968, p > .362). At ketamine doses 






Figure 3.6 Effect of different doses of ketamine (1, 3, 10, and 30 mg/kg) on locomotion in control and 
MIA offspring. Values represent ketamine evoked hyperlocomotion expressed as the relative distance 
moved (∆cm): difference in total distance moved between ketamine and saline control test on the y-
axis; ketamine 1, 3, 10, and 30 mg/kg dose on the x-axis, with error bars indicating the standard error 




We analysed a number of other variables to determine whether there were differences between MIA 
and control rats that could account for the differences in performance (Table 3.1). Separate ANOVA’s 
were conducted for each of the operant behavioural tasks in respect to pellets delivered, lever-press 
latency and head entry latency as the within subjects and group as the between subjects factors. Table 
3.1 contains the results of two-way repeated measures ANOVA for ketamine discrimination, dose-
effect and morphine discrimination tasks. No significant group differences were found for any of the 
respective behavioural tasks. Both MIA and their control counterparts received an equivalent number 
of rewards, therefore the same amount of exposure to the stimulus cue-reward association. No 
differences were found between control and MIA in motivation as indicated by the similar lever-press 
and head-entry latencies, measures of the average time interval between the completion of the first 
FR10 and head-entry into the food magazine, respectively. The only significant effects were found for 
training block. During ketamine discrimination and the dose-effect sessions as training progressed 
both groups of rats received a larger number of rewards per session. Lever-press latency decreased for 
both groups as training progressed in ketamine discrimination and the dose-effect sessions. Head-
entry latency decreased in the dose-effect sessions for both groups of animals. There were no 
interaction effects in any of behavioural tasks indicating that for the significant training block effects 
the lever-press and/or head-entry latency decreased similarly for both groups as the training 
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progressed. Taken together, these results show that the deficit displayed by MIA rats in discriminating 
the psychotomimetic ketamine stimulus cannot be accounted for by a decrease in the number of 
opportunities the rats had to acquire the discrimination, as indicated by the lack of any group 
differences in the number of pellets delivered, or by differences in motivation, as indicated by the 
similarity of MIA and control animals’ lever-press and head-entry latencies. 
 
Table 3.1 Results of Repeated-Measures ANOVA of Rewards Delivered, Lever-
Press and Head-entry latency for Ketamine Discrimination, Dose-Effect and 
Morphine Discrimination  
 Group Training Block Interaction 
Behavioural task F p F p F p 
Ketamine discrimination       
   Rewards delivered 0.04 .846 4.22 <.001 0.66 .746 
   Lever-press latency 0.01 .978 2.17 <.027 2.17 .158 
   Head-entry latency 3.42 .081 1.63 .112 .89 .534 
Dose-effect   Dose   
   Rewards delivered 2.01 .173 3.55 <.001 2.48 .71 
   Lever-press latency 0.09 .764 17.7 <.001 0.05 .948 
   Head-entry latency 22.6 .126 8.14 <.001 1.83 .153 
Morphine discrimination   Training Block   
   Rewards delivered 0.01 .927 .21 .933 .24 .913 
   Lever-press latency 0.9 .365 0.91 .469 0.76 .555 
   Head-entry latency 3.4 .095 0.39 .811 1.05 .329 
Note.   The degrees of freedom; Ketamine discrimination: group F(1,18), training 
block F(9,162), interaction F(9,162). Dose-effect: group F(1,18), dose F(3,54), 
interaction F(3,54). Morphine discrimination: group F(1,10), training block 
F(4,40), interaction F(4,40). Analysis of variance (ANOVA) results are reported 
for the effect of group (maternal immune activation vs control, training block, and 













A key problem with animal models of human psychiatric disorders such as SZ lies with the inability 
of animals to self-report symptoms. Lacking specific biomarkers and objective diagnostic tests, the 
diagnosis of SZ is by necessity conducted through clinical interviews and observation (Kaffman & 
Krystal, 2012). This has meant that researchers have generally been left to monitor in animals 
behaviours that are analogous to core symptoms and make inferences about the underlying 
“subjective” state. As a result, animal models have focused on behavioural measures that either do not 
correspond convincingly to cardinal SZ symptoms, e.g. locomotion activation to a DA releaser or lack 
specificity, e.g. impaired PPI is found across many neurological conditions. Therefore, by challenging 
MIA rats with the psychotomimetic ketamine in a drug discrimination paradigm, our aim was to 
provide an objective measure for an “internal state” in an animal model of SZ.  
 In ketamine discrimination training, MIA rats displayed a lower asymptotic level of accuracy. 
This difference in discrimination was only apparent for ketamine doses in the psychotomimetic range 
(3-10 mg/kg). These results were not due to a general decrease in sensitivity to internal states in MIA 
rats, as these animals readily acquired morphine discrimination, were as sensitive to the internal state 
of satiety and more sensitive to psychogenic ketamine evoked hyperlocomotion. Taken together these 
results suggest that maternal immune activation is a contributing factor to the development of 
psychotic disorders, including SZ. Furthermore, by using a behavioural paradigm where the 
acquisition/discrimination of an internal cue can objectively be measured, we have opened the door to 
the rigorous study of psychosis, which should enable further research into the underlying 
neurocircuitry.  
Aligning with previous research we found a significant reduction in % PPI for MIA offspring 
(Luchicchi et al., 2016; Mattei et al., 2014; Wolff & Bilkey, 2008, 2010), indicating that sensorimotor 
gating is disrupted in rats that were exposed to prenatal immune activation. The reduction in PPI that 
was observed in MIA offspring was neither due to impaired auditory function or mobility, as 
indicated by these animals’ normal responses on startle-only, and prepulse-only trials (Wolff & 
Bilkey, 2008, 2010). Disruptions in PPI is one of the most consistent neurological defects in SZ and is 
observed in approximately 69% of patients (N. R. Swerdlow & Light, 2018). Due to the strong 
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similarity of cross-species effects in modulating PPI, the startle reflex, provides a simple laboratory-
based assay with translational relevance to SZ (Geyer et al., 2001; L. Li, Du, Li, Wu, & Wu, 2009). 
 It is well documented that 7.5 mg/kg of ketamine can act as an internal cue that is reliably 
discriminated from vehicle by rodents (Chiamulera et al., 2016; De Vry & Jentzsch, 2003; Zanos et 
al., 2016). Consistent with previous reports control rats achieved stimulus control within 35-40 
sessions (De Vry & Jentzsch, 2003; Narita, Yoshizawa, Nomura, Aoki, & Suzuki, 2001). With MIA 
rats displaying a significant overall lower asymptomatic level of discrimination accuracy. The plateau 
in discrimination for MIA rats suggested that no further improvements would occur by extending the 
training period. Under the current dosage regime, factors such as responsiveness and tolerance to 
ketamine’s effects are unlikely to account for this deficit in discrimination. For example, Rocha, 
Ward, Egilmez, Lytle, and Emmett-Oglesby (1996) found no shift in the dose-response curve, for rats 
initially trained to discriminate 10 mg/kg ketamine after exposure to chronic injections of 32 mg/kg 
ketamine (every eight hours for a week). Moreover, ketamine has been shown to have marked 
behavioral effects on MIA rats, for example, increased stereotypy, memory impairments and reduced 
PPI (U. Meyer, Nyffeler, Schwendener, et al., 2008; U. Meyer, Nyffeler, Yee, Knuesel, & Feldon, 
2008; Zuckerman & Weiner, 2005). Results from the locomotion assay indicate that MIA rats display 
an overall increase in ketamine evoked hyperlocomotion, with a difference between MIA and control 
rats that were most apparent for doses within the psychotomimetic range (3-10 mg/kg). This finding 
addresses a potential explanation for the discrimination results that MIA animals were merely less 
responsive to ketamine, e.g., due to a down-regulation of NMDAR (Zorumski et al., 2016). Contrary 
to this explanation, at ketamine doses associated with distinct subjective effects from psychosis (1 and 
30 mg/kg) no difference was found between control and MIA, in contrast, for the psychotomimetic 
doses (3 and 10 mg/kg), MIA rats displayed a deficit in ketamine discrimination and were, in fact, 
more sensitive to ketamine-evoked hyperlocomotion (Simões et al., 2018).  
 In view of the ketamine discrimination deficit displayed by MIA rats, we were interested in 
determining whether there was a relationship with % PPI, since impaired PPI has been widely 
reported in connection with psychotic disorders (Cadenhead, Geyer, & Braff, 1993; Geyer et al., 
2001; Kumari, Soni, Mathew, & Sharma, 2000; N. R. Swerdlow et al., 2008). Pearson’s product 
moment correlative analyses were conducted to evaluate potential relationships between the mean 
ketamine discrimination accuracy and the mean % PPI scores.  As seen in Figure 9A, the overall 
statistical analysis of control and MIA combined yielded a significant positive correlation between 
stimulus-appropriate response vs % PPI. The control and MIA groups were then separately analyzed 
since both behavioural indices yielded a significant group deficit for MIA rats and we wanted to test 
whether this correlation was comparable between treatment groups. As seen in Figure 9B, Analysis of 
stimulus-appropriate responses vs % PPI revealed a nonsignificant negative correlation in control and 
a trend for a positive correlation in MIA rats that would reach significance with a larger sample size. 
The observed positive correlation was only apparent for MIA animals and no relationship was found 
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between ketamine discrimination and % PPI for control animals. It is conceivable that in “normal” 
populations downstream compensatory changes in feedback processes may offset otherwise disruptive 
PPI processes (N. Swerdlow, Geyer, & Braff, 2001). If these feedback mechanisms are impaired in 
neurological disorders such as SZ, this may lead to a state of sensory overload with associated 
behavioural deficits (N. R. Swerdlow et al., 2018). Furthermore, human research has indicated that as 
an independent measure PPI is not a reliable diagnostic marker, and levels of PPI neither predict 
treatment response or specific symptoms. Our analysis further confirms that PPI is not “diagnostic” 
and can be misleading when applied as an isolated measure. However, when combined with other 
relevant tests, PPI levels may have an important utility in evaluating animal models relevant to SZ (N. 
R. Swerdlow et al., 2008). 
 
 
Figure 9. Correlation studies between mean % PPI scores and mean percentage correct stimulus-
appropriate responding for (A) the cohort and (B) control and MIA offspring. The regression line in 
scatter plot (A) represents a correlative analysis for the whole cohort N = 20. The two different 
regression lines in scatter plot (B) represent the separate correlative analyses for control N = 10 
(closed blue squares), and MIA N = 10 (closed red circles). Values represent the mean % PPI scores 
on the y-axis; and the mean percentage of correct stimulus-appropriate responses before the first 
reward on the x-axis.  
 
The deficit in discrimination of ketamine for MIA rats was only apparent in the 
psychotomimetic dose range 3-10 mg/kg. A large body of research within drug discrimination has 
established that the training dose selected to establish a discrimination is critical to understanding the 
nature of the stimulus cue (I. P. Stolerman et al., 2011). Few drugs exert only one pharmacological 
effect and the 7.5 mg/kg ketamine training dose was carefully selected as an equivalent dose in 
rodents to that which produces psychotomimetic effects in humans (Autry et al., 2011; Björkman & 
Redke, 2000; N. Li et al., 2010). In both human and animal subjects, ketamine produces dose-
dependent, psychoactive and behavioural effects, e.g., anxiolytic and a delayed anti-depressant effect 
at - low doses, medium doses - acute psychotomimetic effects, and high doses - amnesia/anaesthesia 
(Mion & Villevieille, 2013; Oye et al., 1992). The test doses of ketamine in the dose-effect sessions 
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were selected to produce psychoactive effects that were either congruent (i.e., 3 mg and 10 mg/kg) or 
incongruent (i.e., 1 mg and 30 mg/kg) to the psychotogenic stimulus effects of the training dose.  
 To understand the specificity of a stimulus cue, it is valuable to not only test doses that 
generalize to the training dose but to also test doses that fail to generalize. Without producing any 
group differences in discrimination, ketamine at 1 mg/kg failed to substitute, and at 30 mg/kg 
produced a partial generalization to the 7.5 mg/kg training dose. After receiving the 1 mg/kg dose the 
rats responded predominantly on the vehicle (inert) appropriate lever ~20%. This dose either failed to 
produce psychoactive effects that were distinguishable from vehicle or produced stimulus effects that 
were distinct from the training dose. Previous research in rats has shown that at 1 mg/kg ketamine has 
pronounced anxiolytic effects, without typically producing psychosis (Feder et al., 2014; L.-M. Zhang 
et al., 2015). Drugs with distinct mechanisms of action such as barbiturates and benzodiazepines 
(positive allosteric modulators of GABAA receptor) substitute for low doses of ketamine and the class 
effect of anxiolytics is the common factor in these low dose generalisations (R. A. Glennon & R. 
Young, 2011). In contrast, a medium dose of ketamine shows no pattern of generalisation to 
anxiolytics and will only fully substitute for psychotogenic doses of drugs (including MK-801 and 
PCP) that share a specific mechanism for uncompetitive NMDAR antagonism (I. P. Stolerman et al., 
2011; Willetts, Balster, & Leander, 1990).   
 A drop in drug-appropriate responding occurred at 30mg/kg from the previous 10 mg/kg 
ketamine test dose, this gave the data a non-linear inverted U shape function. This result likely 
indicates that this dose of ketamine produced a qualitatively distinct stimulus effect. At higher doses, 
ketamine produces dissociative stereotypy, behaviours such as circling and side to side head 
movement (head weave) accompanied by ataxia and ambulation (Radford et al., 2017). Ketamine-
induced dissociative stereotypy can have a marked disruption in the animal’s ability to perform the 
task and the 30mg/kg test dose produced a sharp increase in the interresponse interval. Interpreting the 
data requires both a need for caution due to the reduced number of data points and conversely 
signifies by the disruption in behaviour, the appearance of distinct anaesthetic-like effects. The similar 
reduction of responses on the drug designated lever by both MIA and control animals further supports 
this assertion that qualitatively distinct subjective effects occurred at the 30 mg/kg ketamine dose. 
However, it remains to be answered precisely where in rats this demarcation, between doses that exert 
qualitatively, or mechanistically distinct discriminative stimuli, lies. 
 Interoceptive states such as hunger and satiety can also act as discriminative stimuli (Corwin 
et al., 1990; Davidson, 1993). When food and associated stimuli are encountered in the environment, 
these cues can on occasion invoke strong appetitive and consummatory responding and at other 
occasions only weak responding. To explain this pattern of behaviour, it has been proposed that 
animals engage in appetitive and eating behaviour until they become satiated and then refrain from 
making these responses until satiety declines (Amin & Mercer, 2016; Blundell et al., 2010). After 
exposure to a pre-feeding challenge both control and MIA rats displayed a similar reduction in lever-
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presses to food reward. Prenatal immune activation had no effect on the modulation of satiety and 
MIA rats displayed the same degree of sensitivity to a “natural” internal satiety cue as their control 
counterparts. This result provides strong evidence that the deficit in ketamine discrimination was not 
caused by a general lack of ability for MIA rats to discriminate internal cues. 
 A group of drug naïve rats were tested with morphine to evaluate the sensitivity of MIA rats 
to a drug stimulus that is not associated with inducing an acute psychosis (Comfort, 1977; Stefano et 
al., 2012; Verhoeven, Van Praag, Van Ree, & de Wied, 1979). The rationale for using morphine as an 
active control is from the inference that a drug stimulus unrelated to psychosis should be as readily 
discriminable for both groups of rats. Both groups of animals achieved stimulus control within an 
equivalent 30-35 sessions, a result that was consistent with previous research documenting morphine 
as an internal cue that is readily discriminable (Colpaert, 1999; Preston et al., 1989; I. P. Stolerman et 
al., 2011). Morphine is a MOR preferring agonist, one of three opioid receptor types mu, kappa, and 
delta (MOR, KOR, and DOR, respectively) that produce unique actions upon stimulation (Devereaux, 
Mercer, & Cunningham, 2018). Morphine is considered the “gold-standard” treatment for pain, and, 
activation of MOR in the CNS produces subjective effects, including, euphoria and analgesia (Lamb 
et al., 1991; Olds, 1982; Ruiz-Garcia & Lopez-Briz, 2008), that can ameliorate key positive and 
negative SZ symptoms (Comfort, 1977; Gold, Pottash, Sweeney, Martin, & Extein, 1982; Stefano et 
al., 2012; Verhoeven et al., 1979). In comparison, ketamine’s analgesic effects are produced by a 
distinct mechanism through blockade of spinal NMDAR (Petrenko, Yamakura, Baba, & Shimoji, 
2003), with possible secondary effects on DOR (Sarton et al., 2001; Shikanai et al., 2014). MIA rats 
readily acquired the morphine discrimination in an equivalent timeframe to control, thus 
demonstrating, first, that poly I.C. induced MIA did not produce a general impairment in the rat’s 
ability to learn and perform in the drug discrimination procedure. Second, this result provided further 
support for the inference that MIA rats impaired ketamine discrimination is a consequence of the 
similarity of the drugs subjective effects to psychosis. 
In summary, MIA rats displayed a robust deficit in discriminating psychotogenic doses of 
ketamine. No deficit in discrimination was found for a “natural” satiety cue, non-psychotic doses of 
ketamine, or a morphine drug stimulus, supporting the specificity of the relationship of the 
discrimination deficit to psychosis or a psychosis-like state. MIA rats were even more sensitive to 
effects of ketamine in the locomotion assay and this was most apparent for doses within the 
psychotomimetic range (3-10 mg/kg). Furthermore, no differences were found in motivation, with 
both groups of rats attaining equivalent rewards and opportunities to acquire the task (see, Table 3.1). 
The level of experimental control in drug discrimination procedures is enhanced because subjects 
have a similar history of drug exposure and training (Porter et al., 2018; Solinas et al., 2006; I. P. 
Stolerman et al., 2011). Moreover, the controlled environment within an operant chamber prohibits 
the influence of external factors and ensures that success in the task requires the learnt association 
between the internal state induced by a drug (vs vehicle) and the associated lever. 
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 A fundamental principle derived from drug discrimination research states that the acquisition 
of a drug stimuli as an internal cue depends on the ability of the animal to differentiate the 
psychoactive state induced by the drug from their baseline subjective state. (Kangas & Maguire, 2016; 
Preston & Bigelow, 1991). If the internal basal state of MIA rats more closely resembled the 
psychotogenic state induced by ketamine, this similarity of subjective experience would account for 
the deficit in discrimination. A putative mechanistic link between MIA and NMDAR hypofunction is 
provided by two critical findings: 1) the detection of increased basal glutamate levels; e.g., Ibi et al. 
(2009) and Roenker et al. (2011) found pronounced elevations of basal extracellular glutamate in the 
prefrontal cortex and hippocampus of MIA offspring, 2) a ceiling effect for exogenous glutamate 
stimulation; e.g., MK-801 stimulation resulted in a marked blunting in the magnitude of prefrontal 
glutamate release in MIA rats (Roenker et al., 2011) and similarly, for MIA mice in hippocampal K+-
induced glutamate release (Ibi et al., 2009). Mechanisms underlying the effects of MIA on 
glutamatergic function include aberrant NMDA receptor expression and signalling, alterations of DA 
neurons in ventral tegmental area and decreased GABAergic input (U. Meyer, Nyffeler, 
Schwendener, et al., 2008; U. Meyer, Nyffeler, Yee, et al., 2008; Samuelsson, Jennische, Hansson, & 
Holmang, 2006). 
The translational research in rodents is paralleled by findings in SZ patients. Consistent 
elevations are observed in brain glutamate levels, as well as in the combined glutamate/glutamine 
peak (De La Fuente-Sandoval et al., 2011; Egerton et al., 2012; Kim et al., 2018; Merritt, Egerton, 
Kempton, Taylor, & McGuire, 2016). In healthy volunteers and animals, subanaesthetic ketamine 
doses increase extracellular glutamate levels in the prefrontal cortex (up to 200%), in contrast to 
anaesthetic doses that typically produce a decrease (Moghaddam et al., 1997). Lahti et al. (2001) 
demonstrated that in both SZ and healthy volunteer’s subanaesthetic ketamine reliably induces a 
transitory, dose-dependent, increase in Brief Psychiatric Rating Scale (BPRS) scores. However, for 
the withdrawal (negative symptom) subscale only the healthy volunteers experienced a marked 
increase, in comparison the SZ volunteers increase was marginal and non-significant. The higher 
baseline BPRS scores for SZ volunteers suggested a ceiling effect for ketamine in stimulating further 
glutamate release. Lahti et al. (2001) posited that this could be a consequence of increased basal 
glutamate levels in SZ patients from underlying NMDAR dysfunction. In summary, the findings 
presented above demonstrate decreased NMDA receptor function and elevated basal extracellular 
glutamate in the prefrontal cortex, two key features of the NMDA glutamate receptor hypofunction 
model of SZ. 
 It is not clear from our data whether the discrimination deficit is a direct result of MIA alone 
or synergism of MIA and later life chronic ketamine exposure. From the perspective of a two-hit 
model, a prenatal environmental insult acts as a “disease primer” leaving the offspring vulnerable to 
the pathological effects of a “second postnatal-hit”, i.e., chronic ketamine exposure in adulthood 
(Giovanoli et al., 2013; Knuesel et al., 2014; U. Meyer, 2014). Several labs have reported alterations 
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in local inhibitory circuitry as a result of MIA (D. Dickerson et al., 2014; Estes & McAllister, 2016). 
Inhibitory cells are particularly vulnerable to insults during development and disruptions during 
maturation can critically alter the balance of cortical GABA/glutamate plasticity (Hensch, 2005; 
Lisman et al., 2008; O'Donnell, 2011). Studies from post-mortem brain tissue provides strong 
evidence that the GABAergic system is compromised in SZ (Akbarian et al., 1995; Duncan et al., 
2010; Guidotti et al., 2000; Straub et al., 2007; Volk, Austin, Pierri, Sampson, & Lewis, 2000) and 
specific deficits in components of the GABA system are found in the brains of MIA offspring 
(Knuesel et al., 2014; U. Meyer, 2014; Reisinger et al., 2015; Richetto et al., 2016). The GABA 
deficit is restricted mainly to a subtype of fast-spiking parvalbumin interneurons (PVI), that synapse 
on the perisomatic region of pyramidal cells (Beasley, Zhang, Patten, & Reynolds, 2002; Lewis, 
Hashimoto, & Volk, 2005; G. P. Reynolds, Abdul-Monim, Neill, & Zhang, 2004). An exciting recent 
advance is that specific PFC reductions in the marker for the GABA synthesizing enzyme, GAD-67, 
in PVI, has been reported in the brains of adult MIA offspring (Canetta et al., 2016; Knuesel et al., 
2014; U. Meyer, 2014; Z. Zhang & van Praag, 2015). Furthermore, the reduction of inhibition of PV 
cells onto pyramidal neurons is sufficient to cause SZ relevant behaviour in attentional set shifting and 
enhance anxiety-related behaviour in MIA offspring (Canetta et al., 2016). Taken together there is 
strong evidence suggesting that the GABA system is compromised in SZ and MIA is sufficient to 
model some of these SZ-related behavioural vulnerabilities.  
 There is also strong evidence that acute NMDAR antagonism is sufficient to model 
symptomatic SZ and may interact synergistically with MIA to produce long-term neurobiological 
changes. The interaction of inhibitory and excitatory neurons is critical in flexible circuit function 
underlying goal-directed action, perception and cognition (Grace, Floresco, Goto, & Lodge, 2007; 
Lewis et al., 2012; Markram et al., 2004). Bita Moghaddam’s pioneering work on subanaesthetic 
ketamine and cortical disinhibition, posited that ketamine may primarily block NMDARs located on 
inhibitory interneurons, decreasing the activity of fast-spiking PVI and increasing pyramidal cell 
firing through disinhibition, thus leading to a net excitation and corresponding spike in glutamate 
(Homayoun & Moghaddam, 2007; Moghaddam et al., 1997). In support, selective genetic ablation of 
NMDAR on PVI in mice leads to similar SZ-relevant behaviours that occur with global reductions in 
NMDAR (Belforte et al., 2010; J. A. Brown et al., 2015; Fujihara et al., 2015; Korotkova, Fuchs, 
Ponomarenko, von Engelhardt, & Monyer, 2010). Early postnatal treatment with NMDAR antagonists 
also reduces PVI expression in adulthood for both rats (Boctor & Ferguson, 2009; Wang, Yang, Xia, 
& Johnson, 2008) and mice (Nakatani-Pawlak, Yamaguchi, Tatsumi, Mizoguchi, & Yoneda, 2009). In 
summary, ketamine in adulthood has the potential to unmask latent psychopathology in 
neurodevelopmentally vulnerable subjects with prenatal infection histories. 
 A third possibility is ketamine produces a temporally limited (to the duration of drug effects) 
subjective alteration - analogous to human psychosis - in MIA rats, through increasing synaptic 
dopamine. A recent review provides compelling evidence that acute subanaesthetic ketamine 
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administration leads to increased dopamine levels in the frontal cortex, striatum and nucleus 
accumbens of rodents (Kokkinou et al., 2018). NMDAR blockage by ketamine on GABAergic 
interneurons is hypothesised to regulate excitatory projections to midbrain dopamine neurons. 
Specifically, MIA rats have compromised inhibitory circuitry and NMDAR antagonism further 
disinhibits PVI, thus producing a sharper increase in pyramidal cell firing and dopamine neuron 
activation. The maximal increase of dopamine in response to ketamine for rats is estimated to be 50-
400% in the cortex (Kokkinou et al., 2018), compared to amphetamine’s increase of 550-1000% in 
nucleus accumbens (Carboni, Imperato, Perezzani, & Di Chiara, 1989). So, while ketamine acts on 
dopamine it is probably not as potent as amphetamine. For healthy volunteers psychotomimetic 
effects induced by amphetamine only appear after repeated doses (Berman, Kuczenski, McCracken, & 
London, 2009) or a single high dose (Angrist & Gershon, 1970; D. S. Bell, 1973), in a subset of 
individuals. This suggests that amphetamines may act as a stressor to induce psychosis for a 
vulnerable subset of the population (Bramness et al., 2012). In this scenario, the discrimination deficit 
for MIA rats’ can be accounted for in terms of impaired inhibitory circuitry and a susceptibility to 
ketamine misbalancing the mesolimbic dopamine system, leading to increased positive symptoms e.g. 
hallucinations and secondary cognitive impairments e.g. impaired cognitive flexibility (C. Curran et 
al., 2004; Farnia & Golshani, 2016; Waltz, 2017).  This would lead to a disruption in the ability of 
MIA animals to perform in the drug discrimination paradigm specifically at doses of ketamine that 
can produce a human psychosis. 
 It is critical to understand that translational research does not asses an animal model by 
“similarity”, but by the “validity” of inferences to a modelled human disease (Belzung & Lemoine, 
2011). It is important, however, to understand the key limitations for MIA and ketamine in modeling 
SZ. Although epidemiological studies have shown an association of MIA in the development of SZ, 
MIA is not a specific risk factor for a single disorder and prenatal infection has been implicated in 
several neurological disorders, including, ASD, SZ, epilepsy, and neurodegenerative diseases (Estes 
& McAllister, 2016; Harvey & Boksa, 2012). It may be more appropriate to regard MIA as a “primer” 
that, in combination with other genetic and environmental factors may result in the emergence of 
ASD, SZ, or other CNS disorders (U. Meyer, 2014). Poly I.C. immune response is highly variable, 
even after excluding methodological variations. A current concern is that despite the fact poly I.C. is a 
synthetic analogue, there is variation amongst manufacturers in the length and molecular weight and 
that this variability may affect the magnitude of immune responses (Careaga et al., 2018; Zhou et al., 
2013). The original rationale for using poly I.C. in MIA models was based on the assumption that it 
was a universal immune response to all types of viruses and not a specific viral agent that contributed 
to the neurodevelopmental abnormalities. Further research has clarified, for example, that different 
microbial pathogens activate distinct pathways via the activation of different TLR receptors. 
Moreover, while there are significant advantages in using the poly I.C. MIA models, important 
differences may exist with the pathogens encountered in the ecological maternal environment and 
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additional component causes, including, dietary deficiencies, hypoxic and other obstetric insults and 
complications are likely involved (A. S. Brown, 2011; Estes & McAllister, 2016; Kentner et al., 
2018).  
 The psychopathology induced by ketamine broadly overlaps with typical SZ symptoms 
(Krystal et al., 1994; Lahti et al., 2001; Xu et al., 2015). However, no drug model is complete in this 
respect, for example, ketamine tends to produce more visual hallucinations, and auditory 
hallucinations a primary symptom of SZ, are rare (Frohlich & Van Horn, 2016; Javitt, Zukin, 
Heresco-Levy, & Umbricht, 2012; Moghaddam & Krystal, 2012). Ketamine also produces euphoria, 
which is not characteristic of the disorder. In addition, healthy ketamine subjects, unlike SZ patients, 
are usually able to recognise dissociative phenomena as abnormal and attribute them to the drug 
(Vollenweider, Leenders, Øye, Hell, & Angst, 1997). A challenge for the ketamine and MIA model is 
the difficulty of modelling the long-term neurodevelopmental etiopathology of the disorder, an 
important objective for future studies is to develop a paradigm that can effectively test promising SZ 
therapeutics in the prodromal phase, before overt SZ-related behaviours are displayed (Steeds et al., 
2015).  
 To the best of our knowledge, this is the first time in an animal model of SZ, a drug 
discrimination paradigm has been used to interrogate similarities in the subjective effects of a 
psychoactive drug and a basal internal state.  Our results further validate MIA as an animal SZ model 
and illustrate how the drug discrimination paradigm provides a behavioural marker of internal states 
in the absence of verbal self-reports. Due to the promising results of our study, we further plan to do 
post-mortem tissue analysis to compare the consequences of prenatal immune activation with or 
without the addition of postnatal ketamine exposure. To help determine whether the internal state in 
the MIA model is mediated by glutamate, GABA, or dopamine transmission and which brain areas, 
cells and receptor types are critical. In principle, further active controls could be tested with any 
psychoactive drug that is not associated with psychosis. Or conversely, other drugs that induce 
psychotomimesis with distinct pharmacology could be tested, for example, cannabinoids, 
serotoninergic hallucinogens and cholinergic deliriants to probe alternative neurotransmitter 
pathologies associated with the disorder (Barak, 2009; Marona-Lewicka, Nichols, & Nichols, 2011; 
Schneider & Koch, 2003; Steeds et al., 2015). Broadly speaking, this paradigm is adaptable to test any 
number of hypotheses concerning the subjective state of an animal model and interactions with a 
psychoactive drug. Effectively drug discrimination allows for a detailed behaviour readout of how a 
CNS-drug perturbs an animal's internal experience and drugs that generalise, or failure to generalise, 
further specify what neurobiology may underlie the internal cue. 
 Prenatal infection and psychoactive drug exposure, i.e. ketamine, have independently been 
associated with an increased risk for SZ, but research on the cumulative effects of such environmental 
risks is sorely lacking. A comprehensive dose-effect study could identify doses, where single 
exposure to either environmental factor was insufficient but combined, may result in SZ-related 
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behaviours. The MIA drug discrimination paradigm could further elucidate the respective roles that 
glutamate (via NMDAR) and dopamine play in the pathogenesis of SZ. Rats could be treated with 
either NMDA or DA drugs during initial training, or during isolated probe sessions, following drug 
discrimination training. We would hypothesis that normalizing DA and NMDA activity in the MIA 
model will increase the difference between the rats’ subjective state and the ketamine state, leading to 
better drug discrimination, while exacerbating the aberrant signalling will worsen performance. 
Animal testing is essential in preclinical neuropsychiatric drug screening (Dunlop & Brandon, 2015; 
Girgis, Zoghbi, Javitt, & Lieberman, 2018; Reisinger et al., 2015) and the subjective experience of 
psychosis is an essential component for those who suffer from this disorder (Heckers et al., 2013; 
Insel, 2010). A paradigm that can objectively measure an internal cue in an animal model of SZ, has 
the potential to open new translationally relevant avenues in the evaluation of novel SZ therapeutics 
(Dunlop & Brandon, 2015; Leucht et al., 2017; Miyamoto, Duncan, Marx, & Lieberman, 2005) and 
further develop methodologies to probe the underlying physiological changes in the CNS that produce 
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